<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TRI-LO-MARZIA- norgestimate and ethinyl estradiol 
			 </strong><br>Lupin Pharmaceuticals, Inc.<br></p></div>
<h1>Tri-Lo-Marzia</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID154"></a><a name="section-1"></a><p></p>
<p class="First"><a name="ID156"></a><span class="Bold">(norgestimate and ethinyl estradiol tablets USP)</span></p>
<p><span class="Bold">0.180 mg/0.025 mg, 0.215 mg/0.025 mg and 0.250 mg/0.025 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Patients should be counseled that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID157"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID158"></a><a name="section-2.1"></a><p></p>
<p class="First"><a name="ID159"></a>Tri-Lo-Marzia™ (norgestimate and ethinyl estradiol tablets USP) is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. </p>
<p><span class="Bold">Tri-Lo-Marzia </span></p>
<p>Each white film-coated tablet contains 0.180 mg of the progestational compound, norgestimate (+)-13-Ethyl-17-hydroxy-18, 19-dinor-17(-pregn-4-en-20-yn-3-one oxime acetate (ester) and 0.025 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include anhydrous lactose, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol and titanium dioxide. </p>
<p>Each light blue film-coated tablet contains 0.215 mg of the progestational compound norgestimate (+)-13-Ethyl-17-hydroxy-18, 19-dinor-17(-pregn-4-en-20-yn-3-one oxime acetate (ester) and 0.025 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include anhydrous lactose, croscarmellose sodium, FD&amp;C Blue no. aluminium lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol and titanium dioxide.</p>
<p>Each blue film-coated tablet contains 0.250 mg of the progestational compound norgestimate (+)-13-Ethyl-17-hydroxy-18, 19-dinor-17(-pregn-4-en-20-yn-3-one oxime acetate (ester) and 0.025 mg of the estrogenic compound, ethinyl estradiol (19-nor-17(-pregna,1,3,5(10)-trien-20-yne-3,17-diol). Inactive ingredients include anhydrous lactose, croscarmellose sodium, FD&amp;C Blue no. aluminium lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol and titanium dioxide </p>
<p>Each green film-coated tablet contains only inert ingredients, as follows: croscarmellose sodium, FD&amp;C Blue no. aluminium lake, hypromellose, iron oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol and titanium dioxide.</p>
<div class="Figure"><img alt="Norgestimate and Ethinyl Estradiol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44b09714-e619-4829-96b6-b582377cfccf&amp;name=ngm-ee-01-figure-01.jpg"></div>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID161"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section">
<a name="ID162"></a><a name="section-3.1"></a><p></p>
<h2 class="Bold">Oral Contraception</h2>
<p class="First"><a name="ID163"></a>Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation). </p>
<p>Receptor binding studies, as well as studies in animals and humans, have shown that norgestimate and 17-deacetyl norgestimate, the major serum metabolite, combine high progestational activity with minimal intrinsic androgenicity.<span class="Sup">90-93 </span>Norgestimate, in combination with ethinyl estradiol, does not counteract the estrogen-induced increases in <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG), resulting in lower serum testosterone.<span class="Sup">90,91,94</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID164"></a><a name="section-4"></a><p></p>
<h1>PHARMACOKINETICS</h1>
<div class="Section">
<a name="ID165"></a><a name="section-4.1"></a><p></p>
<h2 class="Bold">Absorption</h2>
<p class="First"><a name="ID166"></a>Norgestimate (NGM) and ethinyl estradiol (EE) are rapidly absorbed following oral administration. Norgestimate is rapidly and completely metabolized by first-pass (intestinal and/or hepatic) mechanisms to norelgestromin (NGMN) and norgestrel (NG), which are the major active metabolites of norgestimate. Mean pharmacokinetic parameters for NGMN, NG and EE during three cycles of administration of Tri-Lo-Marzia are summarized in Table 1. These results indicate that: (1) Peak serum concentrations of NGMN and EE were generally reached by 2 hours after dosing; (2) Accumulation following multiple dosing of the 180 mcg NGM / 25 mcg dose is approximately 1.5 to 2 fold for NGMN and approximately 1.5 fold for EE compared with single dose administration, in agreement with that predicted based on linear kinetics of NGMN and EE; (3) The kinetics of NGMN are dose proportional following NGM doses of 180 to 250 mcg; (4) Steady-state conditions for NGMN following each NGM dose and for EE were achieved during the three cycle study; (5) Non-linear accumulation (4.5-14.5 fold) of norgestrel was observed as a result of high affinity binding to SHBG, which limits its biological activity.<span class="Sup">100</span> The effect of food on the pharmacokinetics of Tri-Lo-Marzia has not been studied. </p>
<a name="ID167"></a><table width="98%">
<caption><span>Table 1 provides a summary of norelgestromin, norgestrel and ethinyl estradiol pharmacokinetic parameters.</span></caption>
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<thead><tr class="First Last"><td class="Botrule Toprule" align="center" colspan="7" valign="top">
<span class="Bold">Table </span><span class="Bold">1</span><span class="Bold">: </span><span class="Bold">Mean </span><span class="Bold">(</span><span class="Bold">SD</span><span class="Bold">) </span><span class="Bold">Pharmacokinetic </span><span class="Bold">Parameters </span><span class="Bold">of</span><span class="Bold"><br></span><span class="Bold">Tri</span><span class="Bold">-</span><span class="Bold">Lo</span><span class="Bold">-</span><span class="Bold">Marzia </span><span class="Bold">During </span><span class="Bold">a </span><span class="Bold">Three </span><span class="Bold">Cycle </span><span class="Bold">Study</span><span class="Bold"><br></span>
</td></tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7"><p class="First Footnote">NC = not calculated<br></p></td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>NGMN = Norelgestromin, NG = norgestrel, EE = ethinyl estradiol</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> = peak serum concentration, t<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> = time to reach peak serum concentration, AUC<span class="Sub">0</span><span class="Sub">-</span><span class="Sub">2</span><span class="Sub">4</span><span class="Sub">h</span> = area under serum concentration vs. time curve from 0 to 24 hours, t<span class="Sub">1</span><span class="Sub">/</span><span class="Sub">2</span> = elimination half-life.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>units for all analytes; h = hours</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>units for NGMN and NG – C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> = ng/mL, AUC<span class="Sub">0</span><span class="Sub">-</span><span class="Sub">2</span><span class="Sub">4</span><span class="Sub">h</span> = h.ng/mL</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>units for EE only – C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> = pg/mL, AUC<span class="Sub">0</span><span class="Sub">-</span><span class="Sub">2</span><span class="Sub">4</span><span class="Sub">h</span> = h.pg/mL</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Analyte<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">Cycle</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">Day</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">C<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span></span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">t<span class="Sub">m</span><span class="Sub">a</span><span class="Sub">x</span> </span><span class="Bold">(</span><span class="Bold">h</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">AUC<span class="Sub">0</span></span><span class="Bold"><span class="Sub">-</span></span><span class="Bold"><span class="Sub">2</span><span class="Sub">4</span><span class="Sub">h</span></span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">t<span class="Sub">1</span></span><span class="Bold"><span class="Sub">/</span></span><span class="Bold"><span class="Sub">2</span> </span><span class="Bold">(</span><span class="Bold">h</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">
<span class="Bold">NGMN</span><span class="Bold"><span class="Sup">(</span></span><span class="Bold"><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></span><span class="Bold"><span class="Sup">,</span><span class="Sup"> </span></span><span class="Bold"><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></span><span class="Bold"><span class="Sup">,</span><span class="Sup"> </span></span><span class="Bold"><a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a></span><span class="Bold"><span class="Sup">)</span></span><br>
</td>
<td class="Toprule" align="center" valign="top">
<span class="Bold">1</span><br>
</td>
<td class="Toprule" align="center" valign="top">
<span class="Bold">1</span><br>
</td>
<td class="Toprule" align="center" valign="top">
<span class="Bold">0</span><span class="Bold">.</span><span class="Bold">91 </span>(0.27)<br>
</td>
<td class="Toprule" align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">8 </span>(1.0)<br>
</td>
<td class="Toprule" align="center" valign="top">
<span class="Bold">5</span><span class="Bold">.</span><span class="Bold">86 </span>(1.54)<br>
</td>
<td class="Toprule" align="center" valign="top">
<span class="Bold">NC</span><br>
</td>
</tr>
<tr>
<td align="left" valign="top"><br></td>
<td align="center" valign="top">
<span class="Bold">3</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">7</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">42 </span>(0.43)<br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">8 </span>(0.7)<br>
</td>
<td align="center" valign="top">
<span class="Bold">11</span><span class="Bold">.</span><span class="Bold">3 </span>(3.2)<br>
</td>
<td align="center" valign="top">
<span class="Bold">NC</span><br>
</td>
</tr>
<tr>
<td align="left" valign="top"><br></td>
<td align="center" valign="top"><br></td>
<td align="center" valign="top">
<span class="Bold">14</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">57 </span>(0.39)<br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">8 </span>(0.7)<br>
</td>
<td align="center" valign="top">
<span class="Bold">13</span><span class="Bold">.</span><span class="Bold">9 </span>(3.7)<br>
</td>
<td align="center" valign="top">
<span class="Bold">NC</span><br>
</td>
</tr>
<tr>
<td align="left" valign="top"><br></td>
<td align="center" valign="top"><br></td>
<td align="center" valign="top">
<span class="Bold">21</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">82 </span>(0.54)<br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">5 </span>(0.7)<br>
</td>
<td align="center" valign="top">
<span class="Bold">16</span><span class="Bold">.</span><span class="Bold">1 </span>(4.8)<br>
</td>
<td align="center" valign="top">
<span class="Bold">28</span><span class="Bold">.</span><span class="Bold">1 </span>(10.6)<br>
</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Bold">NG</span><span class="Bold"><span class="Sup">(</span></span><span class="Bold"><a href="#footnote-2" class="Sup">†</a></span><span class="Bold"><span class="Sup">,</span><span class="Sup"> </span></span><span class="Bold"><a href="#footnote-3" class="Sup">‡</a></span><span class="Bold"><span class="Sup">,</span><span class="Sup"> </span></span><span class="Bold"><a href="#footnote-4" class="Sup">§</a></span><span class="Bold"><span class="Sup">)</span></span><br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">0</span><span class="Bold">.</span><span class="Bold">32 </span>(0.14)<br>
</td>
<td align="center" valign="top">
<span class="Bold">2</span><span class="Bold">.</span><span class="Bold">0 </span>(1.1)<br>
</td>
<td align="center" valign="top">
<span class="Bold">2</span><span class="Bold">.</span><span class="Bold">44 </span>(2.04)<br>
</td>
<td align="center" valign="top">
<span class="Bold">NC</span><br>
</td>
</tr>
<tr>
<td align="left" valign="top"><br></td>
<td align="center" valign="top">
<span class="Bold">3</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">7</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">64 </span>(0.89)<br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">9 </span>(0.9)<br>
</td>
<td align="center" valign="top">
<span class="Bold">27</span><span class="Bold">.</span><span class="Bold">9 </span>(18.1)<br>
</td>
<td align="center" valign="top">
<span class="Bold">NC</span><br>
</td>
</tr>
<tr>
<td align="left" valign="top"><br></td>
<td align="center" valign="top"><br></td>
<td align="center" valign="top">
<span class="Bold">14</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">2</span><span class="Bold">.</span><span class="Bold">11 </span>(1.13)<br>
</td>
<td align="center" valign="top">
<span class="Bold">4</span><span class="Bold">.</span><span class="Bold">0 </span>(6.3)<br>
</td>
<td align="center" valign="top">
<span class="Bold">40</span><span class="Bold">.</span><span class="Bold">7 </span>(24.8)<br>
</td>
<td align="center" valign="top">
<span class="Bold">NC</span><br>
</td>
</tr>
<tr>
<td align="left" valign="top"><br></td>
<td align="center" valign="top"><br></td>
<td align="center" valign="top">
<span class="Bold">21</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">2</span><span class="Bold">.</span><span class="Bold">79 </span>(1.42)<br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">7 </span>(1.2)<br>
</td>
<td align="center" valign="top">
<span class="Bold">49</span><span class="Bold">.</span><span class="Bold">9 </span>(27.6)<br>
</td>
<td align="center" valign="top">
<span class="Bold">36</span><span class="Bold">.</span><span class="Bold">4 </span>(10.2)<br>
</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Bold">EE</span><span class="Bold"><span class="Sup">(</span></span><span class="Bold"><a href="#footnote-2" class="Sup">†</a></span><span class="Bold"><span class="Sup">,</span></span><span class="Bold"><a href="#footnote-3" class="Sup">‡</a></span><span class="Bold"><span class="Sup">,</span></span><span class="Bold"><a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a></span><span class="Bold"><span class="Sup">)</span></span><br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">55</span><span class="Bold">.</span><span class="Bold">6 </span>(18.1)<br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">7 </span>(0.5)<br>
</td>
<td align="center" valign="top">
<span class="Bold">421 </span>(118)<br>
</td>
<td align="center" valign="top">
<span class="Bold">NC</span><br>
</td>
</tr>
<tr>
<td align="left" valign="top"><br></td>
<td align="center" valign="top">
<span class="Bold">3</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">7</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">91</span><span class="Bold">.</span><span class="Bold">1 </span>(36.7)<br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">3 </span>(0.3)<br>
</td>
<td align="center" valign="top">
<span class="Bold">782 </span>(329)<br>
</td>
<td align="center" valign="top">
<span class="Bold">NC</span><br>
</td>
</tr>
<tr>
<td align="left" valign="top"><br></td>
<td align="center" valign="top"><br></td>
<td align="center" valign="top">
<span class="Bold">14</span><br>
</td>
<td align="center" valign="top">
<span class="Bold">96</span><span class="Bold">.</span><span class="Bold">9 </span>(38.5)<br>
</td>
<td align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">3 </span>(0.3)<br>
</td>
<td align="center" valign="top">
<span class="Bold">796 </span>(273)<br>
</td>
<td align="center" valign="top">
<span class="Bold">NC</span><br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top"><br></td>
<td class="Botrule" align="center" valign="top"><br></td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">21</span><br>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">95</span><span class="Bold">.</span><span class="Bold">9 </span>(38.9)<br>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">1</span><span class="Bold">.</span><span class="Bold">3 </span>(0.6)<br>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">771 </span>(303)<br>
</td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">17</span><span class="Bold">.</span><span class="Bold">7 </span>(4.4)<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID168"></a><a name="section-4.2"></a><p></p>
<h2 class="Bold">Distribution</h2>
<p class="First"><a name="ID318"></a>Norelgestromin and norgestrel (a serum metabolite of norelgestromin) are highly bound (&gt;97%) to serum proteins. Norelgestromin is bound to albumin and not to SHBG, while norgestrel is bound primarily to SHBG. Ethinyl estradiol is extensively bound (&gt; 97%) to serum albumin.</p>
</div>
<div class="Section">
<a name="ID169"></a><a name="section-4.3"></a><p></p>
<h2 class="Bold">Metabolism</h2>
<p class="First"><a name="ID170"></a>Norgestimate is extensively metabolized by first-pass mechanisms in the gastrointestinal tract and/or liver. Norgestimate’s primary active metabolite is norelgestromin. Subsequent hepatic metabolism of norelgestromin occurs and metabolites include norgestrel, which is also active and various hydroxylated and conjugated metabolites. Ethinyl estradiol is also metabolized to various hydroxylated products and their glucuronide and sulfate conjugates.</p>
</div>
<div class="Section">
<a name="ID171"></a><a name="section-4.4"></a><p></p>
<h2 class="Bold">Excretion</h2>
<p class="First"><a name="ID172"></a>Following 3 cycles of administration of Tri-Lo-Marzia, the mean (± SD) elimination half-life values, at steady-state, for norelgestromin, norgestrel and ethinyl estradiol were 28.1 (± 10.6) hours, 36.4 (±10.2) hours and 17.7 (± 4.4) hours, respectively (Table 1). The metabolites of norelgestromin and ethinyl estradiol are eliminated by renal and fecal pathways.</p>
</div>
<div class="Section">
<a name="ID173"></a><a name="section-4.5"></a><p></p>
<h2 class="Bold">Special Populations</h2>
<div class="Section">
<a name="ID174"></a><a name="section-4.5.1"></a><p></p>
<h3 class="Bold Italics">Effects of Body Weight, Body Surface Area, and Age</h3>
<p class="First"><a name="ID175"></a>The effects of body weight, body surface area, age and race on the pharmacokinetics of norelgestromin, norgestrel and ethinyl estradiol were evaluated in 79 healthy women using pooled data following single dose administration of NGM 180 or 250 mcg / EE 25 mcg tablets in four pharmacokinetic studies. Increasing body weight and body surface area were each associated with decreases in C<span class="Sub">max</span> and AUC<span class="Sub">0-24h</span> values for norelgestromin and ethinyl estradiol and increases in CL/F (oral clearance) for ethinyl estradiol. Increasing body weight by 10 kg is predicted to reduce the following parameters: NGMN C<span class="Sub">max</span> by 9% and AUC<span class="Sub">0-24h</span> by 19%, norgestrel C<span class="Sub">max</span> by 12% and AUC<span class="Sub">0-24h</span> by 46%, EE C<span class="Sub">max</span> by 13% and AUC<span class="Sub">0-24h</span> by 12%. These changes were statistically significant. Increasing age was associated with slight decreases (6% with increasing age by 5 years) in C<span class="Sub">max</span> and AUC<span class="Sub">0-24h</span> for norelgestromin and were statistically significant, but there was no significant effect for norgestrel or ethinyl estradiol. Only a small to moderate fraction (5-40%) of the overall variability in the pharmacokinetics of norelgestromin and ethinyl estradiol following Tri-Lo-Marzia may be explained by any or all of the above demographic parameters.</p>
<p>In clinical studies involving 1673 subjects with a mean weight of 141 pounds, there was no association between pregnancy and weight.</p>
</div>
</div>
<div class="Section">
<a name="ID176"></a><a name="section-4.6"></a><p></p>
<h2 class="Bold">Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"><a name="ID177"></a>No studies with Tri-Lo-Marzia have been conducted in women with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p></p>
</div>
<div class="Section">
<a name="ID178"></a><a name="section-4.7"></a><p></p>
<h2 class="Bold">Drug-Drug Interactions</h2>
<p class="First"><a name="ID179"></a>Although norelgestromin and its metabolites inhibit a variety of P450 enzymes in human liver microsomes, under the recommended dosing regimen, the in vivo concentrations of norelgestromin and its metabolites, even at the peak serum levels, are relatively low compared to the inhibitory constant (K<span class="Sub">i</span>). </p>
<p>Interactions between oral contraceptives and other drugs have been reported in the literature. No formal drug-drug interaction studies were conducted with Tri-Lo-Marzia (see <span class="Bold"><a href="#ID206">PRECAUTIONS</a>).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID180"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID181"></a><a name="section-5.1"></a><p></p>
<p class="First"><a name="ID182"></a>Tri-Lo-Marzia is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. </p>
<p>In an active controlled clinical trial 1,673 subjects completed 11,003 cycles of Tri-Lo-Marzia use and a total of 20 pregnancies were reported in Tri-Lo-Marzia users.<span class="Sup">99</span> This represents an overall use-efficacy (typical user efficacy) pregnancy rate of 2.36 per 100 women-years of use. </p>
<p>Oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the Norplant<span class="Sup">®</span> system, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.</p>
<a name="ID340"></a><table width="99%">
<caption><span>Table 2: Percentage of Women Experiencing an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">Unintended Pregnancy</span> During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States.</span></caption>
<col width="26%">
<col width="24%">
<col width="24%">
<col width="25%">
<thead><tr class="First Last">
<td class="Botrule Toprule" align="center" colspan="1" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="middle">
<span class="Bold">% </span><span class="Bold">of </span><span class="Bold">Women </span><span class="Bold">Experiencing </span><span class="Bold">an </span><span class="Bold"><br></span><span class="Bold">Unintended </span><span class="Bold">Pregnancy </span><span class="Bold">Within </span><span class="Bold">the </span><span class="Bold"><br></span><span class="Bold">First </span><span class="Bold">Year </span><span class="Bold">of </span><span class="Bold">Use</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" colspan="1" valign="middle">
<span class="Bold">% </span><span class="Bold">of </span><span class="Bold">Women </span><span class="Bold"><br></span><span class="Bold">Continuing </span><span class="Bold">Use </span><span class="Bold">at </span><span class="Bold"><br></span><span class="Bold">OneYear<span class="Sup">3</span></span><span class="Bold"><br></span>
</td>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">1</span>Among <span class="Italics">typical </span>couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.<br></p></td></tr>
<tr><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">2</span>Among couples who initiate use of a method (not necessarily for the first time) and who use it <span class="Italics">perfectly </span>(both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.<br></p></td></tr>
<tr><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">3</span>Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year.<br></p></td></tr>
<tr><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">4</span>The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether.<br></p></td></tr>
<tr><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">5</span>Foams, creams, gels, vaginal suppositories, and vaginal film. <br></p></td></tr>
<tr><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">6</span>Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases.<br></p></td></tr>
<tr><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">7</span>With spermicidal cream or jelly.<br></p></td></tr>
<tr><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">8</span>Without spermicides.<br></p></td></tr>
<tr><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">9</span>The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The FDA has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral<span class="Sup">®</span> (1 dose is 2 white pills), Alesse<span class="Sup">®</span> (1 dose is 5 pink pills), Nordette<span class="Sup">®</span> or Levlen<span class="Sup">®</span> (1 dose is 4 yellow pills). <br></p></td></tr>
<tr class="Last"><td align="left" colspan="4"><p class="First Footnote"><span class="Sup">1</span><span class="Sup">0</span>However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age.<br></p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="middle">
<span class="Bold">Method</span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">Typical </span><span class="Bold">Use<span class="Sup">1</span></span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle">
<span class="Bold">Perfect </span><span class="Bold">Use<span class="Sup">2</span></span><span class="Bold"><br></span>
</td>
<td class="Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">
<span class="Bold">(</span><span class="Bold">1</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">2</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">3</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule" align="center" valign="middle">
<span class="Bold">(</span><span class="Bold">4</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="middle">Chance<span class="Sup">4</span><br>
</td>
<td class="Toprule" align="center" valign="middle">85<br>
</td>
<td class="Toprule" align="center" valign="middle">85<br>
</td>
<td class="Toprule" align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Spermicides<span class="Sup">5</span><br>
</td>
<td align="center" valign="middle">26<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">40<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Periodic abstinence<br>
</td>
<td align="center" valign="middle">25<br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle">63<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Calendar<br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Ovulation Method<br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Sympto-Thermal<span class="Sup">6</span><br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle">2<br>
</td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Post-Ovulation<br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle">1<br>
</td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Withdrawal<br>
</td>
<td align="center" valign="middle">19<br>
</td>
<td align="center" valign="middle">4<br>
</td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Cap<span class="Sup">7</span><br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Parous Women<br>
</td>
<td align="center" valign="middle">40<br>
</td>
<td align="center" valign="middle">26<br>
</td>
<td align="center" valign="middle">42<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Nulliparous Women<br>
</td>
<td align="center" valign="middle">20<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">56<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Sponge<br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Parous Women<br>
</td>
<td align="center" valign="middle">40<br>
</td>
<td align="center" valign="middle">20<br>
</td>
<td align="center" valign="middle">42<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Nulliparous Women<br>
</td>
<td align="center" valign="middle">20<br>
</td>
<td align="center" valign="middle">9<br>
</td>
<td align="center" valign="middle">56<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Diaphragm<span class="Sup">7</span><br>
</td>
<td align="center" valign="middle">20<br>
</td>
<td align="center" valign="middle">6<br>
</td>
<td align="center" valign="middle">56<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Condom<span class="Sup">8</span><br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Female (Reality<span class="Sup">®</span>)<br>
</td>
<td align="center" valign="middle">21<br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle">56<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Male<br>
</td>
<td align="center" valign="middle">14<br>
</td>
<td align="center" valign="middle">3<br>
</td>
<td align="center" valign="middle">61<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Pill<br>
</td>
<td align="center" valign="middle">5<br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle">71<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Progestin Only<br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle">0.5<br>
</td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Combined<br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle">0.1<br>
</td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">IUD<br>
</td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
<td align="center" valign="middle"><br></td>
</tr>
<tr>
<td align="left" valign="middle">Progesterone T<br>
</td>
<td align="center" valign="middle">2.0<br>
</td>
<td align="center" valign="middle">1.5<br>
</td>
<td align="center" valign="middle">81<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Copper T380A<br>
</td>
<td align="center" valign="middle">0.8<br>
</td>
<td align="center" valign="middle">0.6<br>
</td>
<td align="center" valign="middle">78<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">LNg 20<br>
</td>
<td align="center" valign="middle">0.1<br>
</td>
<td align="center" valign="middle">0.1<br>
</td>
<td align="center" valign="middle">81<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Depo-Provera<span class="Sup">®</span><br>
</td>
<td align="center" valign="middle">0.3<br>
</td>
<td align="center" valign="middle">0.3<br>
</td>
<td align="center" valign="middle">70<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Norplant<span class="Sup">®</span> and Norplant-2<span class="Sup">®</span><br>
</td>
<td align="center" valign="middle">0.05<br>
</td>
<td align="center" valign="middle">0.05<br>
</td>
<td align="center" valign="middle">88<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Female Sterilization<br>
</td>
<td align="center" valign="middle">0.5<br>
</td>
<td align="center" valign="middle">0.5<br>
</td>
<td align="center" valign="middle">100<br>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">Male Sterilization<br>
</td>
<td class="Botrule" align="center" valign="middle">0.15<br>
</td>
<td class="Botrule" align="center" valign="middle">0.10<br>
</td>
<td class="Botrule" align="center" valign="middle">100<br>
</td>
</tr>
<tr class="Last"><td class="Botrule Toprule" align="left" colspan="4" valign="top">Emergency Contraceptives Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk <br>of pregnancy by at least 75%.<span class="Sup">9</span> <br>Lactation Amenorrhea Method: LAM is a highly effective, temporary method of contraception.<span class="Sup">1</span><span class="Sup">0</span> <br>Source: Trussell J. Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowel D, <br>Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998. <br>
</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID184"></a><a name="section-5.2"></a><p></p>
<p class="First"><a name="ID319"></a><span class="Bold Italics">Tri-Lo-Marzia has not been studied for and is not indicated for use in emergency contraception.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID185"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID186"></a><a name="section-6.1"></a><p></p>
<p class="First"><a name="ID187"></a>Oral contraceptives should not be used in women who have any of the following conditions:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> or thromboembolic disorders</li>
<li>A past history of deep vein <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or thromboembolic disorders</li>
<li>Cerebral vascular or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (current or history)</li>
<li><span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular heart disease</span> with complications</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> with vascular involvement</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> with focal neurological symptoms</li>
<li>Major surgery with prolonged immobilization</li>
<li>Known or suspected carcinoma of the breast or personal history of breast cancer</li>
<li>Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia</li>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> of pregnancy or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> with prior pill use</li>
<li><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or carcinomas</li>
<li>Known or suspected pregnancy</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID189"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Warning">
<a name="ID190"></a><a name="section-7.1"></a><p></p>
<p class="First"><a name="ID191"></a><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID192"></a><a name="section-7.1"></a><p></p>
<p class="First"><a name="ID193"></a>The use of oral contraceptives is associated with increased risks of several serious conditions including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasia</span>, and <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. </p>
<p>Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.</p>
<p>The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined.</p>
<p>Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among nonusers. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and nonusers. The attributable risk does provide information about the actual occurrence of a disease in the population (adapted from refs. 2 and 3 with the author’s permission). For further information, the reader is referred to a text on epidemiological methods.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID194"></a><a name="section-7.2"></a><p></p>
<p class="First"><a name="ID195"></a><span class="Bold">1. Thromboembolic Disorders and Other Vascular Problems</span></p>
<p><span class="Bold Italics">a. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></p>
<p>An increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">morbid obesity</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The relative risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> for current oral contraceptive users has been estimated to be two to six.<span class="Sup">4-10</span> The risk is very low under the age of 30.</p>
<p>Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span> in women in their mid-thirties or older with smoking accounting for the majority of excess cases.<span class="Sup">11</span> Mortality rates associated with circulatory disease have been shown to increase substantially in smokers, especially in those 35 years of age and older and in <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> over the age of 40 among women who use oral contraceptives.</p>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44b09714-e619-4829-96b6-b582377cfccf&amp;name=ngm-ee-01-figure-02.jpg"></div>
<p><a name="ID197"></a>Figure 1 Adapted from P.M. Layde and V. Beral, Ref. #12.</p>
<p>Oral contraceptives may compound the effects of well-known risk factors, such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, age and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>.<span class="Sup">13</span> In particular, some progestogens are known to decrease HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and cause <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>, while estrogens may create a state of <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span>.<span class="Sup">14-18</span> Oral contraceptives have been shown to increase blood pressure among users (see section 9 in <span class="Bold"><a href="#ID189">WARNINGS</a>). </span>Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors.</p>
<p>Norgestimate has minimal androgenic activity (see <span class="Bold"><a href="#ID161">CLINICAL PHARMACOLOGY</a>), </span>and there is some evidence that the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> associated with oral contraceptives is lower when the progestogen has minimal androgenic activity than when the activity is greater.<span class="Sup">97</span></p>
<p><span class="Bold Italics">b. <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></span></p>
<p>An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to nonusers to be 3 for the first episode of superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, 4 to 11 for <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease.<span class="Sup">2,3,19-24</span> Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization.<span class="Sup">25</span> The risk of thromboembolic disease associated with oral contraceptives is not related to length of use and disappears after pill use is stopped.<span class="Sup">2</span></p>
<p>A two- to four-fold increase in relative risk of post-operative thromboembolic complications has been reported with the use of oral contraceptives.<span class="Sup">9</span> The relative risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> in women who have predisposing conditions is twice that of women without such medical conditions.<span class="Sup">26</span> If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, oral contraceptives should be started no earlier than four weeks after delivery in women who elect not to breastfeed.</p>
<p><span class="Bold Italics">c. Cerebrovascular Diseases</span></p>
<p>Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>), although, in general, the risk is greatest among older (&gt;35 years), hypertensive women who also smoke. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> was found to be a risk factor for both users and nonusers, for both types of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, and smoking interacted to increase the risk of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>.<span class="Sup">27-29</span></p>
<p>In a large study, the relative risk of <span class="product-label-link" type="condition" conceptid="4159140" conceptname="Thrombotic stroke">thrombotic strokes</span> has been shown to range from 3 for normotensive users to 14 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.<span class="Sup">30</span> The relative risk of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users and 25.7 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.<span class="Sup">30</span> The attributable risk is also greater in older women.<span class="Sup">3</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID198"></a><a name="section-7.3"></a><p></p>
<p class="First"><a name="ID199"></a><span class="Bold Italics">d. Dose-Related Risk of Vascular Disease from Oral Contraceptives</span></p>
<p>A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease.<span class="Sup">31-33</span> A decline in serum high density lipoproteins (HDL) has been reported with many progestational agents.<span class="Sup">14-16</span> A decline in serum high density lipoproteins has been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>. Because estrogens increase HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestogen and the activity of the progestogen used in the contraceptives. The activity and amount of both hormones should be considered in the choice of an oral contraceptive.</p>
<p>Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular estrogen/progestogen combination, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing the lowest estrogen content which is judged appropriate for an individual patient.</p>
<p><span class="Bold Italics">e. Persistence of Risk of Vascular Disease</span></p>
<p>There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United  States, the risk of developing <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> after discontinuing oral contraceptives persists for at least 9 years for women 40-49 years who had used oral contraceptives for five or more years, but this increased risk was not demonstrated in other age groups.<span class="Sup">8</span> In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small.<span class="Sup">34</span> However, both studies were performed with oral contraceptive formulations containing 50 micrograms or higher of estrogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID200"></a><a name="section-7.4"></a><p></p>
<p class="First"><a name="ID201"></a><span class="Bold">2. Estimates of Mortality from Contraceptive Use</span></p>
<p>One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table 3). These estimates include the combined risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke, and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth. The observation of an increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970’s.<span class="Sup">35</span> Current clinical recommendation involves the use of lower estrogen dose formulations and a careful consideration of risk factors. In 1989, the Fertility and Maternal Health Drugs Advisory Committee was asked to review the use of oral contraceptives in women 40 years of age and over.</p>
<p>The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are also greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception. The Committee recommended that the benefits of low-dose oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks.</p>
<p>Of course, older women, as all women, who take oral contraceptives, should take an oral contraceptive which contains the least amount of estrogen and progestogen that is compatible with a low failure rate and individual patient needs.</p>
<a name="ID202"></a><table width="101%">
<caption><span>Table 3: Annual Number of Birth-Related or Method-Related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> Associated with Control of Fertility per 100,000 Nonsterile Women, by Fertility-Control Method and According to Age</span></caption>
<col width="41%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<col width="10%">
<thead><tr class="First Last">
<td class="Botrule Toprule" align="center" colspan="1" valign="middle">
<span class="Bold">Method </span><span class="Bold">of </span><span class="Bold">control </span><span class="Bold">and </span><span class="Bold">outcome</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" colspan="1" valign="middle">
<span class="Bold">15</span><span class="Bold">-</span><span class="Bold">19</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" colspan="1" valign="middle">
<span class="Bold">20</span><span class="Bold">-</span><span class="Bold">24</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" colspan="1" valign="middle">
<span class="Bold">25</span><span class="Bold">-</span><span class="Bold">29</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" colspan="1" valign="middle">
<span class="Bold">30</span><span class="Bold">-</span><span class="Bold">34</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" colspan="1" valign="middle">
<span class="Bold">35</span><span class="Bold">-</span><span class="Bold">39</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" colspan="1" valign="middle">
<span class="Bold">40</span><span class="Bold">-</span><span class="Bold">44</span><span class="Bold"><br></span>
</td>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="7"><p class="First Footnote">Adapted from H.W. Ory, Family Planning Perspectives, Ref. #35.<br></p></td></tr>
<tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth-related</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method-related</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="middle">No fertility-control methods<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a><br>
</td>
<td class="Toprule" align="center" valign="middle">7.0<br>
</td>
<td class="Toprule" align="center" valign="middle">7.4<br>
</td>
<td class="Toprule" align="center" valign="middle">9.1<br>
</td>
<td class="Toprule" align="center" valign="middle">14.8<br>
</td>
<td class="Toprule" align="center" valign="middle">25.7<br>
</td>
<td class="Toprule" align="center" valign="middle">28.2<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Oral contraceptives, non-smoker<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a><br>
</td>
<td align="center" valign="middle">0.3<br>
</td>
<td align="center" valign="middle">0.5<br>
</td>
<td align="center" valign="middle">0.9<br>
</td>
<td align="center" valign="middle">1.9<br>
</td>
<td align="center" valign="middle">13.8<br>
</td>
<td align="center" valign="middle">31.6<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Oral contraceptives, smoker<a href="#footnote-7" class="Sup">†</a><br>
</td>
<td align="center" valign="middle">2.2<br>
</td>
<td align="center" valign="middle">3.4<br>
</td>
<td align="center" valign="middle">6.6<br>
</td>
<td align="center" valign="middle">13.5<br>
</td>
<td align="center" valign="middle">51.1<br>
</td>
<td align="center" valign="middle">117.2<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">IUD<a href="#footnote-7" class="Sup">†</a><br>
</td>
<td align="center" valign="middle">0.8<br>
</td>
<td align="center" valign="middle">0.8<br>
</td>
<td align="center" valign="middle">1.0<br>
</td>
<td align="center" valign="middle">1.0<br>
</td>
<td align="center" valign="middle">1.4<br>
</td>
<td align="center" valign="middle">1.4<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Condom<a href="#footnote-6" class="Sup">*</a><br>
</td>
<td align="center" valign="middle">1.1<br>
</td>
<td align="center" valign="middle">1.6<br>
</td>
<td align="center" valign="middle">0.7<br>
</td>
<td align="center" valign="middle">0.2<br>
</td>
<td align="center" valign="middle">0.3<br>
</td>
<td align="center" valign="middle">0.4<br>
</td>
</tr>
<tr>
<td align="left" valign="middle">Diaphragm/spermicide<a href="#footnote-6" class="Sup">*</a><br>
</td>
<td align="center" valign="middle">1.9<br>
</td>
<td align="center" valign="middle">1.2<br>
</td>
<td align="center" valign="middle">1.2<br>
</td>
<td align="center" valign="middle">1.3<br>
</td>
<td align="center" valign="middle">2.2<br>
</td>
<td align="center" valign="middle">2.8<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="middle">Periodic abstinence<a href="#footnote-6" class="Sup">*</a><br>
</td>
<td class="Botrule" align="center" valign="middle">2.5<br>
</td>
<td class="Botrule" align="center" valign="middle">1.6<br>
</td>
<td class="Botrule" align="center" valign="middle">1.6<br>
</td>
<td class="Botrule" align="center" valign="middle">1.7<br>
</td>
<td class="Botrule" align="center" valign="middle">2.9<br>
</td>
<td class="Botrule" align="center" valign="middle">3.6<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID203"></a><span class="Bold">3. Carcinoma of the Reproductive Organs and Breasts</span></p>
<p>Numerous epidemiological studies have been performed on the incidence of breast, endometrial, ovarian, and cervical cancer in women using oral contraceptives. </p>
<p>The risk of having breast cancer diagnosed may be slightly increased among current and recent users of combination oral contraceptives. However, this excess risk appears to decrease over time after discontinuation of combination oral contraceptives and by 10 years after cessation the increased risk disappears. Some studies report an increased risk with duration of use while other studies do not and no consistent relationships have been found with dose or type of steroid. Some studies have found a small increase in risk for women who first use combination oral contraceptives before age 20. Most studies show a similar pattern of risk with combination oral contraceptive use regardless of a woman’s reproductive history or her family breast cancer history.</p>
<p>Breast cancers diagnosed in current or previous oral contraceptive users tend to be less clinically advanced than in nonusers.</p>
<p>Women who currently have or have had breast cancer should not use oral contraceptives because breast cancer is usually a hormonally-sensitive tumor.</p>
<p>Some studies suggest that oral contraceptive use has been associated with an increase in the risk of <span class="product-label-link" type="condition" conceptid="198572" conceptname="Cervical intraepithelial neoplasia">cervical intraepithelial neoplasia</span> in some populations of women.<span class="Sup">45-48</span> However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.</p>
<p>In spite of many studies of the relationship between oral contraceptive use and breast and cervical cancers, a cause-and-effect relationship has not been established.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Hepatic Neoplasia</span></span></p>
<p>Benign <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use especially with oral contraceptives of higher dose.<span class="Sup">49</span> Rupture of benign, <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> through intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.<span class="Sup">50,51</span></p>
<p>Studies from Britain have shown an increased risk of developing hepatocellular carcinoma in long-term (&gt;8 years) oral contraceptive users. However, these cancers are extremely rare in the U.S. and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users.</p>
<p><span class="Bold">5. Ocular Lesions</span></p>
<p>There have been clinical case reports of retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>; onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span> or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>; <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID204"></a><a name="section-7.5"></a><p></p>
<p class="First"><a name="ID205"></a><span class="Bold">6. Oral Contraceptive Use Before or During Early Pregnancy</span></p>
<p>Extensive epidemiological studies have revealed no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in women who have used oral contraceptives prior to pregnancy.<span class="Sup">56,57</span> The majority of recent studies also do not indicate a teratogenic effect, particularly in so far as cardiac anomalies and <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">limb reduction defects</span> are concerned,<span class="Sup">55,56,58,59</span> when taken inadvertently during early pregnancy.</p>
<p>The administration of oral contraceptives to induce <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion.</p>
<p>It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period. Oral contraceptive use should be discontinued if pregnancy is confirmed.</p>
<p><span class="Bold">7. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></span></p>
<p>Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens.<span class="Sup">60,61</span> More recent studies, however, have shown that the relative risk of developing <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> among oral contraceptive users may be minimal.<span class="Sup">62-64</span> The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens.</p>
<p><span class="Bold">8. Carbohydrate and Lipid Metabolic Effects</span></p>
<p>Oral contraceptives have been shown to cause a decrease in glucose tolerance in a significant percentage of users.<span class="Sup">17</span> This effect has been shown to be directly related to estrogen dose.<span class="Sup">65</span> Progestogens increase insulin secretion and create <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>, this effect varying with different progestational agents.<span class="Sup">17,66</span> However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose.<span class="Sup">67</span> Because of these demonstrated effects, prediabetic and diabetic women in particular should be carefully monitored while taking oral contraceptives. </p>
<p>A small proportion of women will have persistent <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> while on the pill. As discussed earlier (see <span class="Bold"><a href="#ID195">WARNINGS 1a</a></span>and <span class="Bold"><a href="#ID199">1d</a>), </span>changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users.</p>
<p><span class="Bold">9. Elevated Blood Pressure</span></p>
<p>Women with significant <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> should not be started on hormonal contraception.<span class="Sup">98</span> An increase in blood pressure has been reported in women taking oral contraceptives<span class="Sup">68</span> and this increase is more likely in older oral contraceptive users<span class="Sup">69</span> and with extended duration of use.<span class="Sup">61</span> Data from the Royal College of General Practitioners<span class="Sup">12</span> and subsequent randomized trials have shown that the incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> increases with increasing progestational activity and concentrations of progestogens. </p>
<p>Women with a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>-related diseases, or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span><span class="Sup">70</span> should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives, and there is no difference in the occurrence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> between former and never users.<span class="Sup">68-71</span></p>
<p><span class="Bold">10. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></p>
<p>The onset or exacerbation of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or development of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> with a new pattern which is recurrent, persistent or severe requires discontinuation of oral contraceptives and evaluation of the cause.</p>
<p><span class="Bold">11. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Irregularities</span></p>
<p>Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as in the case of any abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, pregnancy should be ruled out.</p>
<p>Some women may encounter post-pill <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span>, especially when such a condition was preexistent.</p>
<p><span class="Bold">12. <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic Pregnancy</span></span></p>
<p>Ectopic as well as intrauterine pregnancy may occur in contraceptive failures.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID206"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID207"></a><a name="section-8.1"></a><p></p>
<p class="First"><a name="ID208"></a><span class="Bold">1. General</span></p>
<p><span class="Bold">Patients should be counseled that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<p><span class="Bold">2. Physical Examination and Follow-Up</span></p>
<p>It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen and pelvic organs, including cervical <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span>, and relevant laboratory tests. In case of un diagnosed, persistent or recurrent abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> should be monitored with particular care.</p>
<p><span class="Bold">3. Lipid Disorders</span></p>
<p>Women who are being treated for <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> more difficult.</p>
<p><span class="Bold">4. Liver Function</span></p>
<p>If <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops in any woman receiving oral contraceptives, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
<p><span class="Bold">5. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></span></p>
<p>Oral contraceptives may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
<p><span class="Bold">6. <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">Emotional Disorders</span></span></p>
<p>Women with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed and the drug discontinued if <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious degree.</p>
<p><span class="Bold">7. Contact Lenses</span></p>
<p>Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID209"></a><a name="section-8.2"></a><p></p>
<p class="First"><a name="ID210"></a><span class="Bold">8. Drug Interactions</span></p>
<p><span class="Bold Italics">Changes in contraceptive effectiveness associated with co-administration of other products</span></p>
<p>Contraceptive effectiveness may be reduced when hormonal contraceptives are coadministered with antibiotics, anticonvulsants, and other drugs that increase the metabolism of contraceptive steroids. This could result in <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> or breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Examples include rifampin, barbiturates, phenylbutazone, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate, griseofulvin and bosentan. Several cases of contraceptive failure and breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported in the literature with concomitant administration of antibiotics such as ampicillin and tetracyclines. However, clinical pharmacology studies investigating drug interaction between combined oral contraceptives and these antibiotics have reported inconsistent results. </p>
<p>Several of the anti-HIV protease inhibitors have been studied with co-administration of oral combination hormonal contraceptives; significant changes (increase and decrease) in the plasma levels of the estrogen and progestin have been noted in some cases. The safety and efficacy of oral contraceptive products may be affected with coadministration of anti-HIV protease inhibitors. Healthcare professionals should refer to the label of the individual anti-HIV protease inhibitors for further drug-drug interaction information.</p>
<p>Herbal products containing St. John’s Wort (hypericum perforatum) may induce hepatic enzymes (cytochrome P450) and p-glycoprotein transporter and may reduce the effectiveness of contraceptive steroids. This may also result in breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>Concurrent use of bosentan and ethinyl estradiol containing products may result in decreased concentrations of these contraceptive hormones thereby increasing the risk of <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> and unscheduled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p><span class="Bold Italics">Increase in plasma ethinyl estradiol levels associated with co-administered drugs</span></p>
<p>Co-administration of atorvastatin and certain oral contraceptives containing ethinyl estradiol increase AUC values for ethinyl estradiol by approximately 20%. Ascorbic acid and acetaminophen may increase plasma ethinyl estradiol levels, possibly by inhibition of conjugation. CYP 3A4 inhibitors such as itraconazole or ketoconazole may increase plasma hormone levels.</p>
<p><span class="Bold Italics">Changes in plasma levels of co-administered drugs</span></p>
<p>Combination hormonal contraceptives containing some synthetic estrogens (e.g., ethinyl estradiol) may inhibit the metabolism of other compounds. Increased plasma concentrations of cyclosporin, prednisolone, and theophylline have been reported with concomitant administration of oral contraceptives. Decreased plasma concentrations of acetaminophen and increased clearance of temazepam, salicylic acid, morphine and clofibric acid, due to induction of conjugation, have been noted when drugs were administered with oral contraceptives.</p>
<p>Combined hormonal contraceptives have been shown to significantly decrease plasma concentrations of lamotrigine when co-administered due to induction of lamotrigine glucuronidation. This may reduce <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control; therefore, dosage adjustments of lamotrigine may be necessary.<span class="Sup">103</span></p>
<p>Healthcare professionals are advised to also refer to prescribing information of co-administered drugs for recommendations regarding management of concomitant therapy.</p>
<p><span class="Bold">9. Interactions with Laboratory Tests</span></p>
<p>Certain endocrine and liver function tests and blood components may be affected by oral contraceptives: </p>
<p>a. Increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> and factors VII, VIII, IX, and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability.</p>
<p>b. Increased <span class="product-label-link" type="condition" conceptid="4188578" conceptname="Thyroxine binding globulin">thyroid binding globulin</span> (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG, free T4 concentration is unaltered.</p>
<p>c. Other binding proteins may be elevated in serum.</p>
<p>d. <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">Sex hormone binding globulins</span> are increased and result in elevated levels of total circulating sex steroids; however, free or biologically active levels either decrease or remain unchanged.</p>
<p>e. Triglycerides may be increased and levels of various other lipids and lipoproteins may be affected.</p>
<p>f. Glucose tolerance may be decreased.</p>
<p>g. Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives.</p>
<p><span class="Bold">10. Carcinogenesis</span></p>
<p>See <span class="Bold"><a href="#ID189">WARNINGS</a>.</span></p>
<p><span class="Bold">11. Pregnancy</span></p>
<p>Pregnancy Category X. See <span class="Bold"><a href="#ID185">CONTRAINDICATIONS</a></span>and <span class="Bold"><a href="#ID189">WARNINGS</a>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID211"></a><a name="section-8.3"></a><p></p>
<p class="First"><a name="ID212"></a><span class="Bold">12. Nursing Mothers</span></p>
<p>Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers and a few adverse effects on the child have been reported, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use combination oral contraceptives but to use other forms of contraception until she has completely weaned her child.</p>
<p><span class="Bold">13. Pediatric Use</span></p>
<p>Safety and efficacy of Tri-Lo-Marzia have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated.</p>
<p><span class="Bold">14. Geriatric Use</span></p>
<p>This product has not been studied in women over 65 years of age and is not indicated in this population.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID213"></a><a name="section-9"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID214"></a><a name="section-9.1"></a><p></p>
<p class="First"><a name="ID215"></a>See Patient Labeling printed below.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID216"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID217"></a><a name="section-10.1"></a><p></p>
<p class="First"><a name="ID218"></a>An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see <span class="Bold"><a href="#ID189">WARNINGS</a>).</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> and <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></li>
<li>Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span></li>
<li><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span></li>
<li><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span></li>
<li><span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">Cerebral thrombosis</span></li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></li>
<li><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span></li>
</ul>
<p><a name="ID220"></a>There is evidence of an association between the following conditions and the use of oral contraceptives:</p>
<ul>
<li>Mesenteric <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></li>
<li>Retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></li>
</ul>
<p><a name="ID222"></a>The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> (such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>)</li>
<li>Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li>Spotting</li>
<li>Change in menstrual flow</li>
<li><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></li>
<li>Temporary <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> after discontinuation of treatment</li>
<li><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></li>
<li><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span> which may persist</li>
<li>Breast changes: <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, enlargement, secretion</li>
<li>Change in weight (increase or decrease)</li>
<li>Change in cervical erosion and secretion</li>
<li>Diminution in lactation when given immediately postpartum</li>
<li><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span></li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></li>
<li>Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>Reduced tolerance to carbohydrates</li>
<li><span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vaginal candidiasis</span></li>
<li>Change in corneal curvature (steepening)</li>
<li>Intolerance to contact lenses</li>
</ul>
<p><a name="ID224"></a>The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted:</p>
<ul>
<li>Pre-menstrual syndrome</li>
<li><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></li>
<li>Changes in appetite</li>
<li><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>-like syndrome</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span></li>
<li>Loss of scalp hair</li>
<li><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span></li>
<li><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">Erythema nodosum</span></li>
<li>Hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span></li>
<li><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span></li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></li>
<li><span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic uremic syndrome</span></li>
<li><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></li>
<li>Changes in libido</li>
<li><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span></li>
<li>Budd-Chiari Syndrome</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID226"></a><a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID227"></a><a name="section-11.1"></a><p></p>
<p class="First"><a name="ID228"></a>Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID229"></a><a name="section-12"></a><p></p>
<p class="First"><a name="ID230"></a><span class="Bold">NON-CONTRACEPTIVE HEALTH BENEFITS</span></p>
<p>The following non-contraceptive health benefits related to the use of combination oral contraceptives are supported by epidemiological studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg mestranol.<span class="Sup">73-78</span></p>
<p>Effects on menses:</p>
<ul>
<li>increased menstrual cycle regularity</li>
<li>decreased blood loss and decreased incidence of <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span></li>
<li>decreased incidence of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span></li>
</ul>
<p><a name="ID232"></a>Effects related to inhibition of ovulation:</p>
<ul>
<li>decreased incidence of functional <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span></li>
<li>decreased incidence of ectopic pregnancies</li>
</ul>
<p><a name="ID234"></a>Other effects:</p>
<ul>
<li>decreased incidence of fibroadenomas and fibrocystic disease of the breast</li>
<li>decreased incidence of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span></li>
<li>decreased incidence of endometrial cancer</li>
<li>decreased incidence of ovarian cancer</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID236"></a><a name="section-13"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section">
<a name="ID237"></a><a name="section-13.1"></a><p></p>
<h2 class="Bold">Oral Contraception</h2>
<p class="First"><a name="ID238"></a>To achieve maximum contraceptive effectiveness, Tri-Lo-Marzia must be taken exactly as directed and at intervals not exceeding 24 hours. The possibility of ovulation and conception prior to initiation of medication should be considered. Tri-Lo-Marzia is available in the wallet containing 28 tablets which is preset for a Sunday Start. Day 1 Start is also provided.</p>
</div>
<div class="Section">
<a name="ID239"></a><a name="section-13.2"></a><p></p>
<h2>Sunday Start</h2>
<p class="First"><a name="ID240"></a>When taking Tri-Lo-Marzia the first white "active" tablet should be taken on the first Sunday after menstruation begins. If the menstrual period begins on Sunday, the first white "active" tablet should be taken that day. Take one white, light blue or blue "active" tablet daily for 21 days followed by one green "reminder" tablet daily for 7 days. After 28 tablets have been taken, a new course is started the next day (Sunday). For the first cycle of a Sunday Start regimen, another method of contraception should be used until after the first 7 consecutive days of administration.</p>
<p>If the patient misses one (1) white, light blue, or blue "active" tablet in Weeks 1, 2, or 3, the tablet should be taken as soon as she remembers. If the patient misses two (2) white or light blue "active" tablets in Week 1 or Week 2, the patient should take two (2) "active" tablets the day she remembers and two (2) "active" tablets the next day; and then continue taking one (1) tablet a day until she finishes the pack. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills. If the patient misses two (2) blue "active" tablets in the third week or misses three (3) or more "active" tablets in a row, the patient should continue taking one tablet every day until Sunday. On Sunday the patient should throw out the rest of the pack and start a new pack that same day. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills.</p>
<p>Complete instructions to facilitate patient counseling on proper pill usage may be found in the Detailed Patient Labeling ("How to Take the Pill" section).</p>
</div>
<div class="Section">
<a name="ID241"></a><a name="section-13.3"></a><p></p>
<h2>Day 1 Start</h2>
<p class="First"><a name="ID242"></a>The dosage of Tri-Lo-Marzia for the initial cycle of therapy is one white, light blue or blue "active" tablet administered daily from the 1st day through the 21st day of the menstrual cycle, counting the first day of menstrual flow as "Day 1" followed by one green "reminder" tablet daily for 7 days. Tablets are taken without interruption for 28 days. After 28 tablets have been taken, a new course is started the next day.</p>
<p>If the patient misses one (1) white, light blue, or blue "active" tablet in Weeks 1, 2, or 3, the tablet should be taken as soon as she remembers. If the patient misses two (2) white or light blue "active" tablets in Week 1 or Week 2, the patient should take two (2) "active" tablets the day she remembers and two (2) "active" tablets the next day; and then continue taking one (1) tablet a day until she finishes the pack. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills. If the patient misses two (2) blue "active" tablets in the third week or misses three (3) or more "active" tablets in a row, the patient should throw out the rest of the pack and start a new pack that same day. The patient should be instructed to use a back-up method of birth control if she has sex in the seven (7) days after missing pills. </p>
<p>Complete instructions to facilitate patient counseling on proper pill usage may be found in the Detailed Patient Labeling ("How to Take the Pill" section).</p>
<p>When switching from another oral contraceptive, Tri-Lo-Marzia s should be started on the same day that a new pack of the previous oral contraceptive would have been started. </p>
<p>The use of Tri-Lo-Marzia for contraception may be initiated 4 weeks postpartum in women who elect not to breastfeed. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered. (See <span class="Bold"><a href="#ID185">CONTRAINDICATIONS </a></span>and <span class="Bold"><a href="#ID189">WARNINGS</a></span>concerning thromboembolic disease. See also <span class="Bold"><a href="#ID209">PRECAUTIONS for "Nursing Mothers</a>.") </span>The possibility of ovulation and conception prior to initiation of medication should be considered.</p>
<p>(See Discussion of Dose-Related Risk of Vascular Disease from Oral Contraceptives.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID243"></a><a name="section-14"></a><p></p>
<p class="First"><a name="ID244"></a><span class="Bold">ADDITIONAL INSTRUCTIONS FOR ALL DOSING REGIMENS</span></p>
<p>Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, spotting, and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> are frequent reasons for patients discontinuing oral contraceptives. In breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as in all cases of irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina, nonfunctional causes should be borne in mind. In undiagnosed persistent or recurrent abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina, adequate diagnostic measures are indicated to rule out pregnancy or malignancy. If pathology has been excluded, time or a change to another formulation may solve the problem. Changing to an oral contraceptive with a higher estrogen content, while potentially useful in minimizing <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">menstrual irregularity</span>, should be done only if necessary since this may increase the risk of thromboembolic disease.</p>
<p>Use of oral contraceptives in the event of a missed menstrual period:</p>
<p>1. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period and oral contraceptive use should be discontinued if pregnancy is confirmed.</p>
<p>2. If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID245"></a><a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID246"></a><a name="section-15.1"></a><p></p>
<p class="First"><a name="ID247"></a>Tri-Lo-Marzia are available in a wallet (NDC 68180-837-11) containing 28 tablets packed in a pouch (NDC 68180-837-11). Such three pouches are packaged in a carton (NDC 68180-837-13).</p>
<ul>
<li>Each of the 7 white to off white, round, film-coated tablets, debossed with ‘LU’ on one side and "E21" on the other side contains 0.180 mg of the progestational compound, norgestimate, together with 0.025 mg of the estrogenic compound, ethinyl estradiol. </li>
<li>Each of the 7 light blue, round, film-coated tablets, debossed with ‘LU’ on one side and "E22" on the other side contains 0.215 mg of the progestational compound, norgestimate, together with 0.025 mg of the estrogenic compound, ethinyl estradiol. </li>
<li>Each of the 7 blue, round, film-coated tablets, debossed with ‘LU’ on one side and "E23" on the other side contains 0.250 mg of the progestational compound, norgestimate, together with 0.025 mg of the estrogenic compound, ethinyl estradiol. </li>
<li>Each of the 7 green, round, biconvex, film-coated tablets, debossed with ‘LU’ on one side and "E24" on the other side contains inert ingredients.</li>
</ul>
<p><a name="ID249"></a>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [see USP Controlled Room Temperature].</p>
<p>Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID250"></a><a name="section-16"></a><p></p>
<h1>REFERENCES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID251"></a><a name="section-16.1"></a><p></p>
<ol>
<li>Trussell J. Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, <span class="Italics">Contraceptive Technology: Seventeenth Revised Edition. </span>New York NY: Irvington Publishers, 1998. </li>
<li>Stadel BV, Oral contraceptives and cardiovascular disease. (Pt.1). N Engl J Med 1981; 305:612-618. </li>
<li>Stadel BV, Oral contraceptives and cardiovascular disease. (Pt.2). N Engl J Med 1981; 305:672-677. </li>
<li>Adam SA, Thorogood M. Oral contraception and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> revisited: the effects of new preparations and prescribing patterns. Br J Obstet Gynaecol 1981; 88:838-845. </li>
<li>Mann Jl, Inman WH. Oral contraceptives and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. Br Med J 1975; 2(5965):245-248. </li>
<li>Mann Jl, Vessey MP, Thorogood M, Doll R. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> in young women with special reference to oral contraceptive practice. Br Med J 1975; 2(5956):241-245. </li>
<li>Royal College of General Practitioners’ Oral Contraception Study: Further analyses of mortality in oral contraceptive users. Lancet 1981; 1:541-546. </li>
<li>Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD. Risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981:305:420-424. </li>
<li>Vessey MP. Female hormones and vascular disease-an epidemiological overview. Br J Fam Plann 1980; 6(Supplement): 1-12. </li>
<li>Russell-Briefel RG, Ezzati TM, Fulwood R, Perlman JA, Murphy RS. Cardiovascular risk status and oral contraceptive use, United States, 1976-80. Prevent Med 1986; 15:352-362. </li>
<li>Goldbaum GM, Kendrick JS, Hogelin GC, Gentry EM. The relative impact of smoking and oral contraceptive use on women in the United States. JAMA 1987; 258:1339-1342. </li>
<li>Layde PM, Beral V. Further analyses of mortality in oral contraceptive users; Royal College of General Practitioners' Oral Contraception Study. (Table 5) Lancet 1981; 1:541-546. </li>
<li>Knopp RH. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Arteriosclerosis</span> risk: the roles of oral contraceptives and postmenopausal estrogens. J Reprod Med 1986; 31(9) (Supplement):913-921. </li>
<li>Krauss RM, Roy S, Mishell DR, Casagrande J, Pike MC. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses. Am J Obstet 1983; 145:446-452. </li>
<li>Wahl P, Walden C, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B. Effect of estrogen/progestin potency on lipid/lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. N Engl J Med 1983; 308:862-867. </li>
<li>Wynn V, Niththyananthan R. The effect of progestin in combined oral contraceptives on serum lipids with special reference to high density lipoproteins. Am J Obstet Gynecol 1982;142:766-771. </li>
<li>Wynn V, Godsland I. Effects of oral contraceptives on carbohydrate metabolism. J Reprod Med 1986;31(9)(Supplement):892-897. </li>
<li>LaRosa JC. Atherosclerotic risk factors in cardiovascular disease. J Reprod Med 1986;31(9)(Supplement):906-912. </li>
<li>Inman WH, Vessey MP. Investigation of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from pulmonary, coronary, and <span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">cerebral thrombosis</span> and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in women of child-bearing age. Br Med J 1968;2(5599):193-199. </li>
<li>Maguire MG, Tonascia J, Sartwell PE, Stolley PD, Tockman MS. Increased risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> due to oral contraceptives: a further report. Am J Epidemiol 1979;110(2):188-195. </li>
<li>Petitti DB, Wingerd J, Pellegrin F, Ramacharan S. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979;242:1150-1154. </li>
<li>Vessey MP, Doll R, Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 1968;2(5599):199-205. </li>
<li>Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J 1969; 2(5658):651-657. </li>
<li>Porter JB, Hunter JR, Danielson DA, Jick H, Stergachis A. Oral contraceptives and non-fatal vascular disease-recent experience. Obstet Gynecol 1982;59(3):299-302. </li>
<li>Vessey M, Doll R, Peto R, Johnson B, Wiggins P. A long-term follow-up study of women using different methods of contraception: an interim report. J Biosocial Sci 1976;8:375-427. </li>
<li>Royal College of General Practitioners: Oral Contraceptives, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, and <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span>. J Royal Coll Gen Pract 1978; 28:393-399. </li>
<li>Collaborative Group for the Study of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Young Women: Oral contraception and increased risk of <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. N Engl J Med 1973;288:871-878. </li>
<li>Petitti DB, Wingerd J. Use of oral contraceptives, cigarette smoking, and risk of <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>. Lancet 1978;2:234-236. </li>
<li>Inman WH. Oral contraceptives and fatal <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>. Br Med J 1979:2(6203):1468-1470. </li>
<li>Collaborative Group for the Study of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Young Women: Oral Contraceptives and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in young women: associated risk factors. JAMA 1975; 231:718-722. </li>
<li>Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970;2:203-209. </li>
<li>Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 35-mcg oestrogen preparations. Br Med J 1980;280(6224):1157-1161. </li>
<li>Kay CR. Progestogens and arterial disease-evidence from the Royal College of General Practitioners' Study. Am J Obstet Gynecol 1982;142:762-765. </li>
<li>Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. J Royal Coll Gen Pract 1983;33:75-82. </li>
<li>Ory HW. Mortality associated with fertility and fertility control: 1983.Family Planning Perspectives 1983;15:50-56. </li>
<li>The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of breast cancer. N Engl J Med 1986;315:405-411. </li>
<li>Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983;2:926-929. </li>
<li>Paul C, Skegg DG, Spears GFS, Kaldor JM. Oral contraceptives and breast cancer: A national study. Br Med J 1986; 293:723-725. </li>
<li>Miller DR, Rosenberg L, Kaufman DW, Schottenfeld D, Stolley PD, Shapiro S. Breast cancer risk in relation to early oral contraceptive use. Obstet Gynecol 1986;68:863-868. </li>
<li>Olsson H, Olsson ML, Moller TR, Ranstam J, Holm P. Oral contraceptive use and breast cancer in young women in Sweden (letter). Lancet 1985; 1(8431):748-749. </li>
<li>McPherson K, Vessey M, Neil A, Doll R, Jones L, Roberts M. Early contraceptive use and breast cancer: Results of another case-control study. Br J Cancer 1987; 56:653-660. </li>
<li>Huggins GR, Zucker PF. Oral contraceptives and neoplasia; 1987 update. Fertil Steril 1987; 47:733-761. </li>
<li>McPherson K, Drife JO. The pill and breast cancer: why the uncertainty? Br Med J 1986; 293:709-710. </li>
<li>Shapiro S. Oral contraceptives-time to take stock. N Engl J Med 1987; 315:450-451. </li>
<li>Ory H, Naib Z, Conger SB, Hatcher RA, Tyler CW. Contraceptive choice and prevalence of <span class="product-label-link" type="condition" conceptid="192367" conceptname="Dysplasia of cervix">cervical dysplasia</span> and carcinoma in situ. Am J Obstet Gynecol 1976; 124:573-577. </li>
<li>Vessey MP, Lawless M, McPherson K, Yeates D. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill. Lancet 1983; 2:930. </li>
<li>Brinton LA, Huggins GR, Lehman HF, Malli K, Savitz DA, Trapido E, Rosenthal J, Hoover R. Long term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer 1986; 38:339-344. </li>
<li>WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Br Med J 1985; 290:961-965. </li>
<li>Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW. Epidemiology of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span>: the role of oral contraceptive use. JAMA 1979; 242:644-648. </li>
<li>Bein NN, Goldsmith HS. Recurrent massive <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> from benign hepatic tumors secondary to oral contraceptives. Br J Surg 1977; 64:433-435. </li>
<li>Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology 1977; 73:386-394. </li>
<li>Henderson BE, Preston-Martin S, Edmondson HA, Peters RL, Pike MC. Hepatocellular carcinoma and oral contraceptives. Br J Cancer 1983;48:437-440. </li>
<li>Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J 1986; 292:1355-1357. </li>
<li>Forman D, Vincent TJ, Doll R, Cancer of the liver and oral contraceptives. Br Med J 1986; 292:1357-1361. </li>
<li>Harlap S, Eldor J. Births following oral contraceptive failures. Obstet Gynecol 1980; 55:447-452. </li>
<li>Savolainen E, Saksela E, Saxen L. Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 1981: 140:521-524. </li>
<li>Janerich DT, Piper JM, Glebatis DM. Oral contraceptives and <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Am J Epidemiol 1980; 112:73-79. </li>
<li>Ferencz C, Matanoski GM, Wilson PD, Rubin JD, Neill CA, Gutberlet R. Maternal hormone therapy and congenital heart disease. Teratology 1980; 21:225-239. </li>
<li>Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 1979; 109:433-439. </li>
<li>Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, and breast tumors. Lancet 1973; 1:1399-1404. </li>
<li>Royal College of General Practitioners: Oral contraceptives and health. New York, Pittman 1974. </li>
<li>Layde PM, Vessey MP, Yeates D. Risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>: a cohort study of young women attending family planning clinics. J Epidemiol Community Health 1982; 36:274-278. </li>
<li>Rome Group for Epidemiology and Prevention of <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span> (GREPCO): Prevalence of gallstone disease in an Italian adult female population. Am J Epidemiol 1984; 119:796-805. </li>
<li>Storm BL, Tamragouri RT, Morse ML, Lazar EL, West SL, Stolley PD, Jones JK. Oral contraceptives and other risk factors for <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>. Clin Pharmacol Ther 1986; 39:335-341. </li>
<li>Wynn V, Adams PW, Godsland IF, Melrose J, Niththyananthan R, Oakley NW, Seedj A. Comparison of effects of different combined oral contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1979; 1:1045-1049. </li>
<li>Wynn V. Effect of progesterone and progestins on carbohydrate metabolism. In: Progesterone and Progestin. Bardin CW, Milgrom E, Mauvis-Jarvis P. eds. New York, Raven Press 1983; pp. 395-410.</li>
<li>Perlman JA, Roussell-Briefel RG, Ezzati TM, Lieberknecht G. Oral glucose tolerance and the potency of oral contraceptive progestogens. J Chronic Dis 1985;38:857-864. </li>
<li>Royal College of General Practitioners' Oral Contraception Study: Effect on <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1:624. </li>
<li>Fisch IR, Frank J. Oral contraceptives and blood pressure. JAMA 1977; 237:2499-2503. </li>
<li>Laragh AJ. Oral contraceptive induced <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>-nine years later. Am J Obstet Gynecol 1976; 126:141-147. </li>
<li>Ramcharan S, Peritz E, Pellegrin FA, Williams WT. Incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in the Walnut Creek Contraceptive Drug Study cohort: In: Pharmacology of steroid contraceptive drugs. Garattini S, Berendes HW. Eds. New York, Raven Press, 1977; pp. 277-288, (Monographs of the Mario Negri Institute for Pharmacological Research Milan.) </li>
<li>Stockley I. Interactions with oral contraceptives. J Pharm 1976;216:140-143. </li>
<li>The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of ovarian cancer. JAMA 1983; 249:1596-1599. </li>
<li>The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987; 257:796-800. </li>
<li>Ory HW. Functional <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> and oral contraceptives: negative association confirmed surgically. JAMA 1974; 228:68-69. </li>
<li>Ory HW, Cole P, MacMahon B, Hoover R. Oral contraceptives and reduced risk of benign breast disease. N Engl J Med 1976; 294:419-422. </li>
<li>Ory HW. The noncontraceptive health benefits from oral contraceptive use. Fam Plann Perspect 1982; 14:182-184. </li>
<li>Ory HW, Forrest JD, Lincoln R. Making choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, 1983; p.1. </li>
<li>Schlesselman J, Stadel BV, Murray P, Lai S. Breast cancer in relation to early use of oral contraceptives. JAMA 1988; 259:1828-1833. </li>
<li>Hennekens CH, Speizer FE, Lipnick RJ, Rosner B, Bain C, Belanger C, Stampfer MJ, Willett W, Peto R. A case-control study of oral contraceptive use and breast cancer. JNCI 1984; 72:39-42. </li>
<li>LaVecchia C, Decarli A, Fasoli M, Franceschi S, Gentile A, Negri E, Parazzini F, Tognoni G. Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. Br J Cancer 1986; 54:311-317. </li>
<li>Meirik O, Lund E, Adami H, Bergstrom R, Christoffersen T, Bergsjo P. Oral contraceptive use and breast cancer in young women. A Joint National Case-control study in Sweden and Norway. Lancet 1986; 11:650-654. </li>
<li>Kay CR, Hannaford PC. Breast cancer and the pill-A further report from the Royal College of General Practitioners' oral contraception study. Br J Cancer 1988;58:675-680. </li>
<li>Stadel BV, Lai S, Schlesselman JJ, Murray P. Oral contraceptives and premenopausal breast cancer in nulliparous women. Contraception 1988; 38:287-299. </li>
<li>Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S. Breast cancer before age 45 and oral contraceptive use: New Findings. Am J Epidemiol 1989; 129:269-280. </li>
<li>The UK National Case-Control Study Group, Oral contraceptive use and breast cancer risk in young women. Lancet 1989; 1:973-982. </li>
<li>Schlesselman JJ. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 1989; 40:1-38. </li>
<li>Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 1989; 59:613-617. </li>
<li>Jick SS, Walker AM, Stergachis A, Jick H. Oral contraceptives and breast cancer. Br J Cancer 1989; 59:618-621. </li>
<li>Anderson FD, Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives. Acta Obstet Gynecol Scand 1992; 156 (Supplement):15-21. </li>
<li>Chapdelaine A, Desmaris J-L, Derman RJ. Clinical evidence of minimal androgenic activity of norgestimate. Int J Fertil 1989; 34(51):347-352. </li>
<li>Phillips A, Demarest K, Hahn DW, Wong F, McGuire JL. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1989; 41(4):399-409. </li>
<li>Phillips A, Hahn DW, Klimek S, McGuire JL. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1987; 36(2):181-192. </li>
<li>Janaud A, Rouffy J, Upmalis D, Dain M-P. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand 1992; 156 (Supplement):34-38. </li>
<li>Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet1996; 347:1713-1727. </li>
<li>Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S. Oral Contraceptive Use and Liver Cancer. Am J Epidemiol 1989;130:878-882. </li>
<li>Lewis M, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M on behalf of Transnational Research Group on Oral Contraceptives and Health of Young Women. Third generation oral contraceptives and risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>: an international case-control study. Br Med J, 1996;312:88-90. </li>
<li>Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. Geneva, WHO, Family and Reproductive Health, 1996. </li>
<li>Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 2001;63:289-295. </li>
<li>Sitteri PK, Murai JT, Hammond GL, Nisker JA, Raymoure WJ, Huhn RW. The serum transport of steroid hormones. Rec Prog Horm Res 1982;38:457-510.</li>
<li>Bork K, Fischer B, DeWald G. Recurrent episodes of skin <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and severe attacks of <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> induced by oral contraceptives or hormone replacement therapy. Am J Med 2003;114:294-298. </li>
<li>Van Giersbergen PLM, Halabi A, Dingemanse J. <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic interaction</span> between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 2006;44(3):113-118. </li>
<li>Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007;48(3):484-489.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID253"></a><a name="section-17"></a><p></p>
<p class="First"><a name="ID339"></a>Distributed by:</p>
<p><span class="Bold">Lupin Pharmaceuticals, Inc.</span></p>
<p>Baltimore, Maryland 21202</p>
<p>United States</p>
<p>Manufactured by: </p>
<p><span class="Bold">Lupin Limited</span></p>
<p>Pithampur (M.P.) - 454 775</p>
<p>INDIA</p>
<p>July 2012                                                                             ID#: 230064</p>
<p><a name="ID254"></a><span class="Bold">Tri-Lo-Marzia™</span></p>
<p><span class="Bold">(norgestimate and ethinyl estradiol tablets USP)</span></p>
<p><span class="Bold">0.180 mg/0.025 mg, 0.215 mg/0.025 mg and 0.250 mg/0.025 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">BRIEF SUMMARY PATIENT PACKAGE INSERT</span></p>
<p>Oral contraceptives, also known as "birth control pills" or "the pill," are taken to prevent pregnancy. When taken correctly without missing any pills, oral contraceptives are highly effective; however the typical failure rate of large numbers of pill users is 5% per year when women who miss pills are included. Forgetting to take pills considerably increases the chances of pregnancy. For most women oral contraceptives are also free of serious or unpleasant side effects. </p>
<p>For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be fatal or may cause temporary or permanent <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. The risks associated with taking oral contraceptives increase significantly if you: </p>
<ul>
<li>smoke</li>
<li>have high blood pressure, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></li>
<li>have or have had <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">clotting disorders</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, cancer of the breast or sex organs, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or malignant or benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> </li>
</ul>
<p><a name="ID321"></a>Although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy, non-smoking women (even with the newer low-dose formulations), there are also greater potential health risks associated with pregnancy in older women.</p>
<p>You should not take the pill if you suspect you are pregnant or have unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<div class="Warning">
<a name="ID255"></a><a name="section-17.1"></a><p></p>
<p class="First"><a name="ID256"></a><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID257"></a><a name="section-17.1"></a><p></p>
<p class="First"><a name="ID258"></a>Most side effects of the pill are not serious. The most common such effects are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between menstrual periods, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, and difficulty wearing contact lenses. These side effects, especially <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, may subside within the first three months of use.</p>
<p>The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill:</p>
<p>1. Blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), stoppage or rupture of a blood vessel in the brain (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>), blockage of blood vessels in the heart (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>) or other organs of the body. As mentioned above, smoking increases the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and subsequent serious medical consequences.</p>
<p>2. In rare cases, oral contraceptives can cause benign but dangerous <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span>. These benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> can rupture and cause fatal internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In addition, some studies report an increased risk of developing liver cancer. However, liver cancers are rare.</p>
<p>3. High blood pressure, although blood pressure usually returns to normal when the pill is stopped. </p>
<p>The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your healthcare professional if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, bosentan, as well as some anti-convulsants and some antibiotics, and herbal preparations containing St. John’s Wort (hypericum perforatum) may decrease oral contraceptive effectiveness.</p>
<p>Oral contraceptives may interact with lamotrigine (LAMICTAL<span class="Sup">®</span>), an anticonvulsant used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. This may increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> so your healthcare professional may need to adjust the dose of lamotrigine.</p>
<p>Various studies give conflicting reports on the relationship between breast cancer and oral contraceptive use. Oral contraceptive use may slightly increase your chance of having breast cancer diagnosed, particularly after using hormonal contraceptives at a younger age. After you stop using hormonal contraceptives, the chances of having breast cancer diagnosed begin to go back down. You should have regular breast examinations by a healthcare professional and examine your own breasts monthly. Tell your healthcare professional if you have a family history of breast cancer or if you have had breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> or an abnormal mammogram. Women who currently have or have had breast cancer should not use oral contraceptives because breast cancer is usually a hormone-sensitive tumor. </p>
<p>Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. There is insufficient evidence to rule out the possibility that the pill may cause such cancers.</p>
<p>Taking the combination pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, fewer <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infections</span>, and fewer cancers of the ovary and the lining of the uterus.</p>
<p>Be sure to discuss any medical condition you may have with your healthcare professional. Your healthcare professional will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the healthcare professional believes that it is a good medical practice to postpone it. You should be re examined at least once a year while taking oral contraceptives. Your pharmacist should have given you the detailed patient information labeling which gives you further information which you should read and discuss with your healthcare professional.</p>
<p><span class="Bold">Tri-Lo-Marzia (like all oral contraceptives) is intended to prevent pregnancy. Oral contraceptives do not protect against transmission of HIV (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> such as chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID259"></a><a name="section-17.2"></a><p></p>
<p class="First"><a name="ID260"></a><span class="Bold">HOW TO TAKE THE PILL</span></p>
<p><span class="Bold">IMPORTANT POINTS TO REMEMBER</span></p>
<p><span class="Underline">BEFORE </span>YOU START TAKING YOUR PILLS:</p>
<p>1. BE SURE TO READ THESE DIRECTIONS:</p>
<p>Before you start taking your pills.</p>
<p>Anytime you are not sure what to do.</p>
<p>2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME.</p>
<p>If you miss pills you could get pregnant. This includes starting the pack late.</p>
<p>The more pills you miss, the more likely you are to get pregnant.</p>
<p>3. MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS. If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn’t go away, check with your healthcare professional.</p>
<p>4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even when you make up these missed pills. </p>
<p>On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.</p>
<p>5. IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OR <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your pills may not work as well.</p>
<p>Use a back-up method (such as condom or spermicide) until you check with your healthcare professional.</p>
<p>6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your healthcare professional about how to make pill-taking easier or about using another method of birth control. </p>
<p>7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your healthcare professional.</p>
<p><span class="Bold Underline">BEFORE </span><span class="Bold">YOU START TAKING YOUR PILLS</span></p>
<p>1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL.</p>
<p>It is important to take it at about the same time every day.</p>
<p>2. The 28-pill pack has 21 white, light blue, and blue "active" pills (with hormones) to take for 3 weeks. This is followed by 1 week of green "reminder" pills (without hormones).</p>
<p>3. ALSO FIND:</p>
<p>1) where on the pack to start taking pills,</p>
<p>2) in what order to take the pills.</p>
<div class="Figure"><img alt="If your period begins on a day other than Sunday, place the day label strip that starts with the first day of your period here." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44b09714-e619-4829-96b6-b582377cfccf&amp;name=ngm-ee-01-figure-03.jpg"></div>
<p><a name="ID262"></a>*For use of day labels, see <span class="Bold">WHEN TO START THE </span>FIRST <span class="Bold">PACK OF PILLS </span>below.</p>
<p>4. BE SURE YOU HAVE READY AT ALL TIMES: </p>
<p>ANOTHER KIND OF BIRTH CONTROL (such as condom or spermicide) to use as a back-up method in case you miss pills.</p>
<p>AN EXTRA, FULL PILL PACK.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID263"></a><a name="section-17.3"></a><p></p>
<p class="First"><a name="ID264"></a><span class="Bold">WHEN TO START THE FIRST PACK OF PILLS</span></p>
<p>You have a choice of which day to start taking your first pack of pills. Tri-Lo-Marzia is available in a wallet. Decide with your healthcare professional which is the best day for you. Pick a time of day that will be easy to remember.</p>
<p><span class="Bold">Sunday Start:</span></p>
<ol>
<li>Pick the day label strip that starts with the first day of your period. Place this day label strip over the area that has the days of the week (starting with Sunday) pre-printed on the wallet.</li>
<li>Take the first white "active" pill of the pack on the <span class="Underline">Sunday after your period starts</span><span class="Italics">, </span>even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins on Sunday, start the pack that same day.</li>
</ol>
<p><a name="ID266"></a><span class="Underline">Use another method of birth control </span>(such as condom or spermicide) as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days).</p>
<p><span class="Bold">Day 1 Start:</span></p>
<p>Take the first white "active" pill of the first pack during the <span class="Underline">first 24 hours of your period</span>.</p>
<p>You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period.</p>
<p><span class="Bold">WHAT TO DO DURING THE MONTH</span></p>
<p><span class="Bold">1. Take One Pill At The Same Time Every Day Until The Pack Is Empty</span></p>
<p>Do not skip pills even if you are spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between monthly periods or feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>).</p>
<p>Do not skip pills even if you do not have sex very often.</p>
<p><span class="Bold">2. When You Finish A Pack Or Switch Your Brand Of Pills</span></p>
<p>Start the next pack on the day after your last green "reminder" pill. Do not wait any days between packs.</p>
<p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<p>If you <span class="Bold">MISS 1 </span>white, light blue or blue "active" pill:</p>
<p>1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day.</p>
<p>2. You do not need to use a back-up birth control method if you have sex.</p>
<p>If you <span class="Bold">MISS 2 </span>white or light blue "active" pills in a row in <span class="Bold">WEEK 1 OR WEEK 2 </span>of your pack:</p>
<p>1. Take 2 pills on the day you remember and 2 pills the next day.</p>
<p>2. Then take 1 pill a day until you finish the pack.</p>
<p>3. You COULD BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condom or spermicide) as a back-up method for those 7 days.</p>
<p>If you <span class="Bold">MISS 2 </span>blue "active" pills in a row in <span class="Bold">THE 3RD WEEK:</span></p>
<p>1. <span class="Bold">If you are a Sunday Starter:</span></p>
<p>Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.</p>
<p><span class="Bold">If you are a Day 1 Starter:</span></p>
<p>THROW OUT the rest of the pill pack and start a new pack that same day.</p>
<p>2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your healthcare professional because you might be pregnant.</p>
<p>3. You COULD BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or spermicide) as a back-up method for those 7 days.</p>
<p>If you <span class="Bold">MISS 3 OR MORE </span>white, light blue or blue "active" pills in a row (during the first 3 weeks):</p>
<p>1. <span class="Bold">If you are a Sunday Starter:</span></p>
<p>Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.</p>
<p><span class="Bold">If you are a Day 1 Starter:</span></p>
<p>THROW OUT the rest of the pill pack and start a new pack that same day.</p>
<p>2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your healthcare professional because you might be pregnant.</p>
<p>3. You COULD BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condom or spermicide) as a back-up method for those 7 days.</p>
<p>If you forget any of the 7 green "reminder" pills in Week 4:</p>
<p>THROW AWAY the pills you missed.</p>
<p>Keep taking 1 pill each day until the pack is empty.</p>
<p>You do not need a back-up method.</p>
<p><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: </span>Use a BACK-UP METHOD anytime you have sex.</p>
<p>KEEP TAKING ONE "ACTIVE" PILL EACH DAY until you can reach your healthcare professional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID267"></a><a name="section-17.4"></a><p></p>
<p class="First"><a name="ID268"></a><span class="Bold">INSTRUCTIONS FOR USING YOUR WALLET</span></p>
<p><span class="Bold">Please Read Me!</span></p>
<ul class="Square">
<li>Sunday Start or </li>
<li>Day 1 Start</li>
</ul>
<p><a name="ID329"></a>There are two ways to start taking birth control pills: Sunday Start or Day 1 Start.</p>
<p>Your healthcare provider will tell you which to use.</p>
<p><span class="Bold">Save these instructions.</span></p>
<p>1. <span class="Bold">If this is the first time </span>you are taking birth control pills, or if you have not taken birth control pills for 10 days or more, your first step is to <span class="Bold">wait until the first day you get your menstrual period. </span>Then, follow these instructions for either Sunday Start or Day 1 Start.</p>
<p>2. <span class="Bold">When you get your period:</span></p>
<ul>
<li>You will use a <span class="Bold">Sunday Start </span>if your doctor told you to take your first pill on a Sunday. Take pill "1" on the Sunday after your period starts. If your period starts on a Sunday, take pill "1" that day.</li>
<li>You will use a <span class="Bold">Day 1 Start </span>if your doctor told you to take pill "1" on the first day of your period.</li>
</ul>
<p><a name="ID323"></a>3. <span class="Bold">Remove pill "1" </span>by pushing down on the pill. The pill will come out through a hole in the back of the strip. </p>
<p>4. <span class="Bold">Swallow the pill. </span>You will take one pill each day. If you use a Sunday Start and you are taking the pill for the FIRST TIME, YOU MUST USE A BACK-UP METHOD OF BIRTH CONTROL FOR THE FIRST 7 DAYS. If you use a Day 1 Start, you are protected from becoming pregnant as soon as you take your first pill. </p>
<p>5. Wait 24 hours to take your next pill. Continue to take one pill each day until all the pills have been taken.</p>
<p>6. <span class="Bold">Take your pill at the same time every day. </span>It is important to take the correct pill each day and not miss any pills. To help you remember, take your pill at the same time as another daily activity, like turning off your alarm clock or brushing your teeth.</p>
<p>7. <span class="Bold">When your wallet is empty. </span>You will start a new wallet on the day after pill "28."</p>
<p>8. THE FIRST PILL IN EVERY WALLET WILL ALWAYS BE TAKEN ON THE SAME DAY OF THE WEEK, NO MATTER WHEN YOUR NEXT PERIOD STARTS.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID269"></a><a name="section-17.5"></a><p></p>
<p class="First"><a name="ID270"></a><span class="Bold">DETAILED PATIENT LABELING</span></p>
<p><span class="Bold">PLEASE NOTE: This labeling is revised from time to time as important new medical information becomes available. Therefore, please review this labeling carefully.</span></p>
<p>Tri-Lo-Marzia</p>
<p>Each white film-coated tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol.</p>
<p>Each light blue film-coated tablet contains 0.215 mg norgestimate and 0.025 mg ethinyl estradiol.</p>
<p>Each blue film-coated tablet contains 0.250 mg norgestimate and 0.025 mg ethinyl estradiol.</p>
<p>Each green film-coated tablet contains inert ingredients.</p>
</div>
<div class="Section">
<a name="ID271"></a><a name="section-17.6"></a><p></p>
<h2 class="Bold">INTRODUCTION</h2>
<p class="First"><a name="ID272"></a>Any woman who considers using oral contraceptives (the birth control pill or the pill) should understand the benefits and risks of using this form of birth control. This patient labeling will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this labeling is not a replacement for a careful discussion between you and your healthcare professional. You should discuss the information provided in this labeling with him or her, both when you first start taking the pill and during your revisits. You should also follow your healthcare professional’s advice with regard to regular check-ups while you are on the pill.</p>
</div>
<div class="Section">
<a name="ID273"></a><a name="section-17.7"></a><p></p>
<h2 class="Bold">EFFECTIVENESS OF ORAL CONTRACEPTIVES FOR CONTRACEPTION</h2>
<p class="First"><a name="ID274"></a>Oral contraceptives or "birth control pills" or "the pill" are used to prevent pregnancy and are more effective than most other non-surgical methods of birth control. When taken correctly without missing any pills, oral contraceptives are highly effective; however, typical failure rates are 5% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle.</p>
<p>In comparison, typical failure rates for other non-surgical methods of birth control during the first year of use are as follows:</p>
<p>Implant: &lt;1%</p>
<p>Injection: &lt;1%</p>
<p>IUD: 1 to 2%</p>
<p>Diaphragm with spermicides: 20%</p>
<p>Spermicides alone: 26%</p>
<p>Vaginal sponge: 20 to 40%</p>
<p>Female sterilization: &lt;1%</p>
<p>Male sterilization: &lt;1%</p>
<p>Cervical Cap with spermicide: 20 to 40%</p>
<p>Condom alone (male): 14%</p>
<p>Condom alone (female): 21%</p>
<p>Periodic abstinence: 25%</p>
<p>No methods: 85%</p>
<p>Withdrawal: 19%</p>
<p><a name="ID276"></a><span class="Bold">WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES</span></p>
</div>
<div class="Warning">
<a name="ID277"></a><a name="section-17.8"></a><p></p>
<p class="First"><a name="ID278"></a><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID279"></a><a name="section-17.8"></a><p></p>
<p class="First"><a name="ID280"></a>Some women should not use the pill. You should not use the pill if you have any of the following conditions:</p>
<ul>
<li>A history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>Blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), or eyes</li>
<li>A history of blood clots in the deep veins of your legs</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>)</li>
<li>Known or suspected breast cancer or cancer of the lining of the uterus, cervix or vagina</li>
<li>Unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> (until a diagnosis is reached by your healthcare professional)</li>
<li>Yellowing of the whites of the eyes or of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) during pregnancy or during previous use of the pill</li>
<li><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumor</span> (benign or cancerous)</li>
<li>Known or suspected pregnancy</li>
<li>If you plan to have surgery with prolonged bedrest</li>
</ul>
<p><a name="ID282"></a>Tell your healthcare professional if you have ever had any of these conditions. Your healthcare professional can recommend a safer method of birth control.</p>
</div>
<div class="Section">
<a name="ID283"></a><a name="section-17.9"></a><p></p>
<h2 class="Bold">OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES</h2>
<p class="First"><a name="ID284"></a>Tell your healthcare professional if you have or have had:</p>
<ul>
<li>Breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, fibrocystic disease of the breast, an abnormal breast x-ray or mammogram</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></li>
<li>Elevated <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglycerides</li>
<li>High blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> or other <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span></li>
<li>Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>Gallbladder, liver, heart or kidney disease</li>
<li>History of scanty or irregular menstrual periods</li>
</ul>
<p><a name="ID286"></a>Women with any of these conditions should be checked often by their healthcare professional if they choose to use oral contraceptives.</p>
<p>Also, be sure to inform your healthcare professional if you smoke or are on any medications.</p>
</div>
<div class="Section">
<a name="ID287"></a><a name="section-17.10"></a><p></p>
<h2 class="Bold">RISKS OF TAKING ORAL CONTRACEPTIVES</h2>
<p class="First"><a name="ID288"></a><span class="Bold">1. Risk of Developing Blood Clots</span></p>
<p>Blood clots and blockage of blood vessels are one of the most serious side effects of taking oral contraceptives and can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. In particular, a clot in the legs can cause <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> and a clot that travels to the lungs can cause a sudden blocking of the vessel carrying blood to the lungs. Rarely, clots occur in the blood vessels of the eye and may cause <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, or impaired vision.</p>
<p>If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness or injury or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your healthcare professional about stopping oral contraceptives four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least four weeks after delivery if you are not breastfeeding. If you are breastfeeding, you should wait until you have weaned your child before using the pill. (See also the section on Breastfeeding in General Precautions.)</p>
<p>The risk of circulatory disease in oral contraceptive users may be higher in users of high-dose pills and may be greater with longer duration of oral contraceptive use. In addition, some of these increased risks may continue for a number of years after stopping oral contraceptives. The risk of abnormal blood clotting increases with age in both users and nonusers of oral contraceptives, but the increased risk from the oral contraceptive appears to be present at all ages. For women aged 20 to 44 it is estimated that about 1 in 2,000 using oral contraceptives will be hospitalized each year because of abnormal clotting. Among nonusers in the same age group, about 1 in 20,000 would be hospitalized each year. For oral contraceptive users in general, it has been estimated that in women between the ages of 15 and 34 the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to a circulatory disorder is about 1 in 12,000 per year, whereas for nonusers the rate is about 1 in 50,000 per year. In the age group 35 to 44, the risk is estimated to be about 1 in 2,500 per year for oral contraceptive users and about 1 in 10,000 per year for nonusers.</p>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart Attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Strokes</span></span></p>
<p>Oral contraceptives may increase the tendency to develop <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> (stoppage or rupture of blood vessels in the brain) and <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> (blockage of blood vessels in the heart). Any of these conditions can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.</p>
<p>Smoking greatly increases the possibility of suffering <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></span></p>
<p>Oral contraceptive users probably have a greater risk than nonusers of having <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, although this risk may be related to pills containing high doses of estrogens.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver Tumors</span></span></p>
<p>In rare cases, oral contraceptives can cause benign but dangerous <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span>. These benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> can rupture and cause fatal internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In addition, some studies report an increased risk of developing liver cancer. However, liver cancers are rare.</p>
<p><span class="Bold">5. Cancer of the Reproductive Organs and Breasts</span></p>
<p>Various studies give conflicting reports on the relationship between breast cancer and oral contraceptive use. Oral contraceptive use may slightly increase your chance of having breast cancer diagnosed, particularly after using hormonal contraceptives at a younger age. After you stop using hormonal contraceptives, the chances of having breast cancer diagnosed begin to go back down. You should have regular breast examinations by a healthcare professional and examine your own breasts monthly. Tell your healthcare professional if you have a family history of breast cancer or if you have had breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> or an abnormal mammogram. Women who currently have or have had breast cancer should not use oral contraceptives because breast cancer is usually a hormone-sensitive tumor.</p>
<p>Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. There is insufficient evidence to rule out the possibility that the pill may cause such cancers.</p>
</div>
<div class="Section">
<a name="ID289"></a><a name="section-17.11"></a><p></p>
<h2 class="Bold">ESTIMATED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> FROM A BIRTH CONTROL METHOD OR PREGNANCY</h2>
<p class="First"><a name="ID290"></a>All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. An estimate of the number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with different methods of birth control and pregnancy has been calculated and is shown in the following table.</p>
<a name="ID291"></a><table width="98%">
<col width="41%">
<col width="9%">
<col width="9%">
<col width="9%">
<col width="9%">
<col width="10%">
<col width="11%">
<thead><tr class="First Last"><td class="Botrule Toprule" align="left" colspan="7" valign="top">
<span class="Bold">Table </span><span class="Bold">4</span><span class="Bold">: </span><span class="Bold">Annual </span><span class="Bold">Number </span><span class="Bold">of </span><span class="Bold">Birth</span><span class="Bold">-</span><span class="Bold">Related </span><span class="Bold">or </span><span class="Bold">Method</span><span class="Bold">-</span><span class="Bold">Related </span><span class="Bold">Deaths </span><span class="Bold">Associated </span><span class="Bold">with </span><span class="Bold">Control </span><span class="Bold">of </span><span class="Bold">Fertility </span><span class="Bold">per </span><span class="Bold">100</span><span class="Bold">,</span><span class="Bold">000 </span><span class="Bold">Nonsterile </span><span class="Bold">Women</span><span class="Bold">, </span><span class="Bold">by </span><span class="Bold">Fertility</span><span class="Bold">-</span><span class="Bold">Control </span><span class="Bold">Method </span><span class="Bold">and </span><span class="Bold">According </span><span class="Bold">to </span><span class="Bold">Age</span><span class="Bold"><br></span>
</td></tr></thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth-related</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method-related</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Method </span><span class="Bold">of </span><span class="Bold">control </span><span class="Bold">and </span><span class="Bold">outcome</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">15</span><span class="Bold">-</span><span class="Bold">19</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">20</span><span class="Bold">-</span><span class="Bold">24</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">25</span><span class="Bold">-</span><span class="Bold">29</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">30</span><span class="Bold">-</span><span class="Bold">4</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">35</span><span class="Bold">-</span><span class="Bold">39</span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<span class="Bold">40</span><span class="Bold">-</span><span class="Bold">44</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">No fertility-control methods<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a><br>
</td>
<td class="Toprule" align="center" valign="top">7.0<br>
</td>
<td class="Toprule" align="center" valign="top">7.4<br>
</td>
<td class="Toprule" align="center" valign="top">9.1<br>
</td>
<td class="Toprule" align="center" valign="top">14.8<br>
</td>
<td class="Toprule" align="center" valign="top">25.7<br>
</td>
<td class="Toprule" align="center" valign="top">28.2<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Oral contraceptives, non-smoker<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a><br>
</td>
<td align="center" valign="top">0.3<br>
</td>
<td align="center" valign="top">0.5<br>
</td>
<td align="center" valign="top">0.9<br>
</td>
<td align="center" valign="top">1.9<br>
</td>
<td align="center" valign="top">13.8<br>
</td>
<td align="center" valign="top">31.6<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Oral contraceptives, smoker<a href="#footnote-9" class="Sup">†</a><br>
</td>
<td align="center" valign="top">2.2<br>
</td>
<td align="center" valign="top">3.4<br>
</td>
<td align="center" valign="top">6.6<br>
</td>
<td align="center" valign="top">13.5<br>
</td>
<td align="center" valign="top">51.1<br>
</td>
<td align="center" valign="top">117.2<br>
</td>
</tr>
<tr>
<td align="left" valign="top">IUD<a href="#footnote-9" class="Sup">†</a><br>
</td>
<td align="center" valign="top">0.8<br>
</td>
<td align="center" valign="top">0.8<br>
</td>
<td align="center" valign="top">1.0<br>
</td>
<td align="center" valign="top">1.0<br>
</td>
<td align="center" valign="top">1.4<br>
</td>
<td align="center" valign="top">1.4<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Condom<a href="#footnote-8" class="Sup">*</a><br>
</td>
<td align="center" valign="top">1.1<br>
</td>
<td align="center" valign="top">1.6<br>
</td>
<td align="center" valign="top">0.7<br>
</td>
<td align="center" valign="top">0.2<br>
</td>
<td align="center" valign="top">0.3<br>
</td>
<td align="center" valign="top">0.4<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Diaphragm/spermicide<a href="#footnote-8" class="Sup">*</a><br>
</td>
<td align="center" valign="top">1.9<br>
</td>
<td align="center" valign="top">1.2<br>
</td>
<td align="center" valign="top">1.2<br>
</td>
<td align="center" valign="top">1.3<br>
</td>
<td align="center" valign="top">2.2<br>
</td>
<td align="center" valign="top">2.8<br>
</td>
</tr>
<tr>
<td align="left" valign="top">Periodic abstinence<a href="#footnote-8" class="Sup">*</a><br>
</td>
<td align="center" valign="top">2.5<br>
</td>
<td align="center" valign="top">1.6<br>
</td>
<td align="center" valign="top">1.6<br>
</td>
<td align="center" valign="top">1.7<br>
</td>
<td align="center" valign="top">2.9<br>
</td>
<td align="center" valign="top">3.6<br>
</td>
</tr>
<tr class="Last"><td class="Botrule Toprule" align="left" colspan="7" valign="top">Adapted from H.W. Ory, Family Planning Perspectives, Ref. #35.<br>
</td></tr>
</tbody>
</table>
<p><a name="ID324"></a>In the above table, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was highest with pregnancy (7-26 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, depending on age). Among pill users who do not smoke, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group.</p>
<p>The suggestion that women over 40 who do not smoke should not take oral contraceptives is based on information from older, higher-dose pills. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of low-dose oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. Older women, as all women, who take oral contraceptives, should take an oral contraceptive which contains the least amount of estrogen and progestogen that is compatible with the individual patient needs.</p>
</div>
<div class="Section">
<a name="ID292"></a><a name="section-17.12"></a><p></p>
<h2>WARNING SIGNALS</h2>
<p class="First"><a name="ID293"></a>If any of these adverse effects occur while you are taking oral contraceptives, call your healthcare professional immediately:</p>
<ul>
<li>Sharp <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> of blood, or sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> (indicating a possible clot in the lung)</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in the calf (indicating a possible clot in the leg)</li>
<li>Crushing <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or heaviness in the chest (indicating a possible <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>)</li>
<li>Sudden severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, disturbances of vision or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in an arm or leg (indicating a possible <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>)</li>
<li>Sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> (indicating a possible clot in the eye)</li>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> (indicating possible breast cancer or fibrocystic disease of the breast; ask your healthcare professional to show you how to examine your breasts)</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> in the stomach area (indicating a possibly ruptured <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span>) </li>
<li>Difficulty in sleeping, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, lack of energy, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or change in mood (possibly indicating severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> or a yellowing of the skin or eyeballs, accompanied frequently by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, loss of appetite, dark colored urine, or light colored bowel movements (indicating possible liver problems)</li>
</ul>
</div>
<div class="Section">
<a name="ID294"></a><a name="section-17.13"></a><p></p>
<h2 class="Bold">SIDE EFFECTS OF ORAL CONTRACEPTIVES</h2>
<p class="First"><a name="ID295"></a><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></span></p>
<p>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting may occur while you are taking the pills. Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may vary from slight staining between menstrual periods to breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which is a flow much like a regular period. Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may be temporary and usually does not indicate any serious problems. It is important to continue taking your pills on schedule. If the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs in more than one cycle or lasts for more than a few days, talk to your healthcare professional.</p>
<p><span class="Bold">2. Contact Lenses</span></p>
<p>If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your healthcare professional.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></span></p>
<p>Oral contraceptives may cause <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>) with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the fingers or ankles and may raise your blood pressure. If you experience <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, contact your healthcare professional.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span></span></p>
<p>A spotty darkening of the skin is possible, particularly of the face, which may persist.</p>
<p><span class="Bold">5. Other Side Effects</span></p>
<p>Other side effects may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, change in appetite, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of scalp hair, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infections</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
<p>If any of these side effects bother you, call your healthcare professional.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="ID296"></a><a name="section-17.14"></a><p></p>
<h2>GENERAL PRECAUTIONS</h2>
<p class="First"><a name="ID297"></a><span class="Bold">1. Missed Periods and Use of Oral Contraceptives Before or During Early Pregnancy</span></p>
<p>There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your healthcare professional. If you have not taken the pills daily as instructed and missed a menstrual period, you may be pregnant. If you missed two consecutive menstrual periods, you may be pregnant. Check with your healthcare professional immediately to determine whether you are pregnant. Stop taking oral contraceptives if pregnancy is confirmed.</p>
<p>There is no conclusive evidence that oral contraceptive use is associated with an increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, but these findings have not been seen in more recent studies. Nevertheless, oral contraceptives should not be used during pregnancy. You should check with your healthcare professional about risks to your unborn child of any medication taken during pregnancy.</p>
<p><span class="Bold">2. While Breastfeeding</span></p>
<p>If you are breastfeeding, consult your healthcare professional before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breastfeeding. You should use another method of contraception since breastfeeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breastfeed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely.</p>
<p><span class="Bold">3. Laboratory Tests</span></p>
<p>If you are scheduled for any laboratory tests, tell your healthcare professional you are taking birth control pills. Certain blood tests may be affected by birth control pills.</p>
<p><span class="Bold">4. Drug Interactions</span></p>
<p>Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Such drugs include rifampin, drugs used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> such as barbiturates (for example, phenobarbital), topiramate (TOPAMAX<span class="Sup">®</span>), carbamazepine (Tegretol<span class="Sup">®</span> is one brand of this drug), or phenytoin (Dilantin<span class="Sup">®</span> is one brand of this drug); phenylbutazone (Butazolidin<span class="Sup">®</span> is one brand); certain drugs used in the treatment of HIV or AIDS; and possibly certain antibiotics. Medicine for <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, such as bosentan (Tracleer<span class="Sup">®</span>). Pregnancies and breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported by women who also used some form of the herbal supplement St. John’s Wort while using combined hormonal contraceptives. Hormonal contraceptives may interact with lamotrigine (LAMICTAL<span class="Sup">®</span>), an anticonvulsant used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. This may increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> so your healthcare professional may need to adjust the dose of lamotrigine. You may need to use additional contraception when you take other products which can make oral contraceptives less effective. Be sure to tell your healthcare professional if you are taking or start taking any medications while taking birth control pills.</p>
<p><span class="Bold">5. <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually Transmitted Diseases</span></span></p>
<p><span class="Bold">Tri-Lo-Marzia (like all oral contraceptives) is intended to prevent pregnancy. Oral contraceptives do not protect against transmission of HIV (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> such as chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</span></p>
</div>
<div class="Section">
<a name="ID298"></a><a name="section-17.15"></a><p></p>
<h2 class="Bold">HOW TO TAKE THE PILL</h2>
<p class="First"><a name="ID299"></a><span class="Bold">IMPORTANT POINTS TO REMEMBER</span></p>
<p><span class="Underline">BEFORE </span>YOU START TAKING YOUR PILLS:</p>
<p>1. BE SURE TO READ THESE DIRECTIONS:</p>
<p>Before you start taking your pills.</p>
<p>Anytime you are not sure what to do.</p>
<p>2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME.</p>
<p>If you miss pills you could get pregnant. This includes starting the pack late.</p>
<p>The more pills you miss, the more likely you are to get pregnant.</p>
<p>3. MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1-3 PACKS OF PILLS. If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn’t go away, check with your healthcare professional.</p>
<p>4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even when you make up these missed pills.</p>
<p>On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach.</p>
<p>5. IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OR <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your pills may not work as well.</p>
<p>Use a back-up method (such as condom or spermicide) until you check with your healthcare professional.</p>
<p>6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your healthcare professional about how to make pill-taking easier or about using another method of birth control.</p>
<p>7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your healthcare professional.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID300"></a><a name="section-17.16"></a><p></p>
<p class="First"><a name="ID301"></a><span class="Bold Underline">BEFORE </span><span class="Bold">YOU START TAKING YOUR PILLS</span></p>
<p>1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL.</p>
<p>It is important to take it at about the same time every day.</p>
<p>2. The pill pack has 21 white, light blue, and blue "active" pills (with hormones) to take for 3 weeks. This is followed by 1 week of green "reminder" pills (without hormones).</p>
<p>3. ALSO FIND: </p>
<p>1) where on the pack to start taking pills,</p>
<p>2) in what order to take the pills.</p>
<div class="Figure"><img alt="If your period begins on a day other than Sunday, place the day label strip that starts with the first day of your period here." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44b09714-e619-4829-96b6-b582377cfccf&amp;name=ngm-ee-01-figure-04.jpg"></div>
<p><a name="ID303"></a><span class="Sup">*</span>For use of day labels, see <span class="Bold">WHEN TO START THE FIRST PACK OF PILLS </span>below.</p>
<p>4. BE SURE YOU HAVE READY AT ALL TIMES: </p>
<p>ANOTHER KIND OF BIRTH CONTROL (such as condoms or spermicide) to use as a back-up method in case you miss pills.</p>
<p>AN EXTRA, FULL PILL PACK.</p>
<p><span class="Bold">WHEN TO START THE FIRST PACK OF PILLS</span></p>
<p>You have a choice of which day to start taking your first pack of pills. Tri-Lo-Marzia is available in a wallet. Decide with your healthcare professional which is the best day for you. Pick a time of day that will be easy to remember.</p>
<p><span class="Bold">Sunday Start:</span></p>
<ol>
<li>Pick the day label strip that starts with the first day of your period. Place this day label strip over the area that has the days of the week (starting with Sunday) pre-printed on the wallet.</li>
<li>Take the first white "active" pill of the pack on the <span class="Underline">Sunday after your period starts</span><span class="Italics">, </span>even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins on Sunday, start the pack that same day.</li>
</ol>
<p><a name="ID305"></a><span class="Underline">Use another method of birth control </span>(such as condom or spermicide) as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days).</p>
<p><span class="Bold">Day 1 Start:</span></p>
<p>Take the first white "active" pill of the first pack during the <span class="Underline">first 24 hours of your period</span>.</p>
<p>You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID306"></a><a name="section-17.17"></a><p></p>
<p class="First"><a name="ID307"></a><span class="Bold">WHAT TO DO DURING THE MONTH</span></p>
<p><span class="Bold">1. Take One Pill At The Same Time Every Day Until The Pack Is Empty</span></p>
<p>Do not skip pills even if you are spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between monthly periods or feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>).</p>
<p>Do not skip pills even if you do not have sex very often.</p>
<p><span class="Bold">2. When You Finish A Pack Or Switch Your Brand Of Pills</span></p>
<p>Start the next pack on the day after your last green "reminder" pill. Do not wait any days between packs.</p>
<p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<p>If you <span class="Bold">MISS 1 </span>white, light blue or blue "active" pill:</p>
<p>1. Take it as soon as you remember. Take the next pill at your regular time. This means you may take 2 pills in 1 day.</p>
<p>2. You do not need to use a back-up birth control method if you have sex.</p>
<p>If you <span class="Bold">MISS 2 </span>white or light blue "active" pills in a row in <span class="Bold">WEEK 1 OR WEEK 2 </span>of your pack:</p>
<p>1. Take 2 pills on the day you remember and 2 pills the next day.</p>
<p>2. Then take 1 pill a day until you finish the pack.</p>
<p>3. You COULD BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condom or spermicide) as a back-up method for those 7 days.</p>
<p>If you <span class="Bold">MISS 2 </span>blue "active" pills in a row in <span class="Bold">THE 3RD WEEK:</span></p>
<p>1. <span class="Bold">If you are a Sunday Starter:</span></p>
<p>Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.</p>
<p><span class="Bold">If you are a Day 1 Starter:</span></p>
<p>THROW OUT the rest of the pill pack and start a new pack that same day.</p>
<p>2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your healthcare professional because you might be pregnant.</p>
<p>3. You COULD BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condoms or spermicide) as a back-up method for those 7 days.</p>
<p>If you <span class="Bold">MISS 3 OR MORE </span>white, light blue or blue "active" pills in a row (during the first 3 weeks):</p>
<p>1. <span class="Bold">If you are a Sunday Starter:</span></p>
<p>Keep taking 1 pill every day until Sunday. On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day.</p>
<p><span class="Bold">If you are a Day 1 Starter:</span></p>
<p>THROW OUT the rest of the pill pack and start a new pack that same day.</p>
<p>2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your healthcare professional because you might be pregnant.</p>
<p>3. You COULD BECOME PREGNANT if you have sex in the 7 days after you miss pills. You MUST use another birth control method (such as condom or spermicide) as a back-up method for those 7 days.</p>
<p>If you forget any of the 7 green "reminder" pills in Week 4:</p>
<p>THROW AWAY the pills you missed.</p>
<p>Keep taking 1 pill each day until the pack is empty.</p>
<p>You do not need a back-up method.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID308"></a><a name="section-17.18"></a><p></p>
<p class="First"><a name="ID309"></a><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED: </span>Use a BACK-UP METHOD anytime you have sex.</p>
<p>KEEP TAKING ONE "ACTIVE" PILL EACH DAY until you can reach your healthcare professional.</p>
<p><span class="Bold">PREGNANCY DUE TO PILL FAILURE</span></p>
<p>When taken correctly without missing any pills, oral contraceptives are highly effective; however the typical failure rate of large numbers of pill users is 5% per year when women who miss pills are included. If failure does occur, the risk to the fetus is minimal.</p>
<p><span class="Bold">PREGNANCY AFTER STOPPING THE PILL</span></p>
<p>There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">irregular menstrual cycles</span> before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy.</p>
<p>There does not appear to be any increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in newborn babies when pregnancy occurs soon after stopping the pill.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID310"></a><a name="section-17.19"></a><p></p>
<h2>OVERDOSAGE</h2>
<p class="First"><a name="ID311"></a>Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in females. In case of overdosage, contact your healthcare professional or pharmacist.</p>
</div>
<div class="Section">
<a name="ID312"></a><a name="section-17.20"></a><p></p>
<h2 class="Bold">OTHER INFORMATION</h2>
<p class="First"><a name="ID313"></a>Your healthcare professional will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the healthcare professional believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your healthcare professional if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your healthcare professional, because this is a time to determine if there are early signs of side effects of oral contraceptive use.</p>
<p>Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills.</p>
</div>
<div class="Section">
<a name="ID314"></a><a name="section-17.21"></a><p></p>
<h2 class="Bold">HEALTH BENEFITS FROM ORAL CONTRACEPTIVES</h2>
<p class="First"><a name="ID315"></a>In addition to preventing pregnancy, use of combination oral contraceptives may provide certain benefits. They are:</p>
<ul>
<li>menstrual cycles may become more regular</li>
<li>blood flow during menstruation may be lighter and less iron may be lost. Therefore, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> due to <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> is less likely to occur</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or other symptoms during menstruation may be encountered less frequently</li>
<li>ectopic (tubal) pregnancy may occur less frequently</li>
<li>noncancerous <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> or lumps in the breast may occur less frequently</li>
<li>acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> may occur less frequently</li>
<li>oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus</li>
</ul>
<p><a name="ID327"></a>If you want more information about birth control pills, ask your healthcare professional or pharmacist. They have a more technical leaflet called the Professional Labeling, which you may wish to read. The professional labeling is also published in a book entitled <span class="Italics">Physicians’ Desk Reference, </span>available in many bookstores and public libraries.</p>
<p>Tri-Lo-Marzia™ is a trademark of Lupin Pharmaceuticals, Inc.</p>
<p>The other brands listed are trademarks of their respective owners and are not trademarks of Lupin Pharmaceuticals, Inc. The makers of these brands are not affiliated with and do not endorse Lupin Pharmaceuticals, Inc. or its products.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID316"></a><a name="section-18"></a><p></p>
<p class="First"><a name="ID317"></a>Distributed by:</p>
<p><span class="Bold">Lupin Pharmaceuticals, Inc.</span></p>
<p>Baltimore, Maryland 21202</p>
<p>United States</p>
<p>Manufactured by:</p>
<p><span class="Bold">Lupin Limited</span></p>
<p>Pithampur (M.P.) - 454 775</p>
<p>INDIA</p>
<p>July 2012                                                                             ID#: 230063</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID330"></a><a name="section-19"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><a name="ID331"></a><span class="Bold">Tri-Lo-Marzia™</span></p>
<p><span class="Bold">(norgestrimate and ethinyl estradiol tablets USP)</span></p>
<p><span class="Bold">0.180 mg/0.025 mg; 0.0215 mg/0.025 mg and 0.250 mg/0.025 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">NDC 68180-837-11</span></p>
<p><span class="Bold">Wallet Label: 28 Tablets </span></p>
<div class="Figure"><img alt="Tri-Lo-Marzia
(norgestrimate and ethinyl estradiol tablets USP)
0.180 mg/0.025 mg; 0.0215 mg/0.025 mg and 0.250 mg/0.025 mg
Rx Only
NDC 68180-837-11
																			Wallet Label: 28 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44b09714-e619-4829-96b6-b582377cfccf&amp;name=ngm-ee-01-figure-05.jpg"></div>
<p><a name="ID333"></a><span class="Bold">Tri-Lo-Marzia™</span></p>
<p><span class="Bold">(norgestrimate and ethinyl estradiol tablets USP)</span></p>
<p><span class="Bold">0.180 mg/0.025 mg; 0.0215 mg/0.025 mg and 0.250 mg/0.025 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">NDC 68180-837-11</span></p>
<p><span class="Bold">Pouch Label: 1 Wallet of 28 Tablets </span></p>
<div class="Figure"><img alt="Tri-Lo-Marzia
(norgestrimate and ethinyl estradiol tablets USP)
0.180 mg/0.025 mg; 0.0215 mg/0.025 mg and 0.250 mg/0.025 mg
Rx Only
NDC 68180-837-11
																			Pouch Label: 1 Wallet of 28 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44b09714-e619-4829-96b6-b582377cfccf&amp;name=ngm-ee-01-figure-06.jpg"></div>
<p><a name="ID335"></a><span class="Bold">Tri-Lo-Marzia™</span></p>
<p><span class="Bold">(norgestrimate and ethinyl estradiol tablets USP)</span></p>
<p><span class="Bold">0.180 mg/0.025 mg; 0.0215 mg/0.025 mg and 0.250 mg/0.025 mg</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">NDC 68180-837-13</span></p>
<p><span class="Bold">Carton Label: 3 Wallets of 28 Tablets</span></p>
<div class="Figure"><img alt="Tri-Lo-Marzia
(norgestrimate and ethinyl estradiol tablets USP)
0.180 mg/0.025 mg; 0.0215 mg/0.025 mg and 0.250 mg/0.025 mg
Rx Only
NDC 68180-837-13
																			Carton Label: 3 Wallets of 28 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=44b09714-e619-4829-96b6-b582377cfccf&amp;name=ngm-ee-01-figure-07.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TRI-LO-MARZIA 		
					</strong><br><span class="contentTableReg">norgestimate and ethinyl estradiol kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68180-837</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68180-837-13</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68180-837-11</td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 4</strong></td>
<td class="formItem"> </td>
<td class="formItem">7 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>TRI-LO-MARZIA 		
					</strong><br><span class="contentTableReg">norgestimate and ethinyl estradiol tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NORGESTIMATE</strong> (NORGESTIMATE) </td>
<td class="formItem">NORGESTIMATE</td>
<td class="formItem">0.18 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.025 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LU;E21</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200541</td>
<td class="formItem">08/22/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>TRI-LO-MARZIA 		
					</strong><br><span class="contentTableReg">norgestimate and ethinyl estradiol tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NORGESTIMATE</strong> (NORGESTIMATE) </td>
<td class="formItem">NORGESTIMATE</td>
<td class="formItem">0.215 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.025 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Light blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LU;E22</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200541</td>
<td class="formItem">08/22/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>TRI-LO-MARZIA  		
					</strong><br><span class="contentTableReg">norgestimate and ethinyl estradiol tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NORGESTIMATE</strong> (NORGESTIMATE) </td>
<td class="formItem">NORGESTIMATE</td>
<td class="formItem">0.25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.025 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LU;E23</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200541</td>
<td class="formItem">08/22/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 4 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>INERT 		
					</strong><br><span class="contentTableReg">inert tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (Green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Round) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LU;E24</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200541</td>
<td class="formItem">08/22/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA200541</td>
<td class="formItem">08/22/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Lupin Pharmaceuticals, Inc.
							(089153071)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>94036a51-72bc-4fad-9aaa-d997d3d3880e</div>
<div>Set id: 44b09714-e619-4829-96b6-b582377cfccf</div>
<div>Version: 4</div>
<div>Effective Time: 20120822</div>
</div>
</div> <div class="DistributorName">Lupin Pharmaceuticals, Inc.</div></p>
</body></html>
